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Steady state levels of mRNAs are determined by the rate of synthesis 
and degradation. A well-known cis-element conferring instability to 
mRNA is the so-called AU-rich element (ARE), which is present in 
the 3’ untranslated region (3’UTR) of many cytokines, chemokines, 
growth factors or proto-oncogenes. The ARE is recognized by a 
variety of ARE-binding proteins (AUBPs), which decide about the 
fate of the RNA. Multiple signaling cascades regulate the activity 
of the AUBPs. Butyrate response factor 1 (BRF1), a Tis11 protein 
family member, was functionally cloned in our lab, as an ARE-mRNA 
destabilizing protein. However, not much is known about the mode of 
action of this protein and its physiological role.
This thesis deals in a fi rst part with the regulation of BRF1. 
Analysis of BRF1 protein sequence revealed multiple putative 
phosphorylation sites, where BRF1 activity could be regulated. 
Serine 92 (S92) was identifi ed by coworkers as a protein kinase B 
(PKB/Akt) phosphorylation site. To confi rm this fi nding in vivo a 
phospho-specifi c antibody was raised in rabbits. Using this antibody, 
phosphorylation of S92 could be corroborated in vivo. Further, it 
could be shown that ARE-containing mRNA is stabilized under 
conditions of phosphorylated BRF1. Inhibitor experiments indicated 
that S92 is not only phosphorylated by PKB, but also by at least one 
other kinase, probably from the ERK1/2 MAPK pathway. Apart from 
S92, also other sites seem to be phosphorylated, as arsenite-treatment 
of mouse fi broblasts (NIH3T3) or insulin-treatment of rat fi broblasts, 
which overexpress the human insulin receptor (HIRc-B), result in a 
protein phosphatase sensitive shift of BRF1 on SDS-PAGE. These 
additional phosphorylation events were analyzed in a second part. 
Comparison of the sequence of all three Tis11 protein family members 
revealed that S203 in BRF1 is homologous to the MK2 target site 
S178 in TTP. Indeed, S203 seems to be phosphorylated. Inhibitor 
experiments suggested that the ERK pathway might be involved. 
In addition, mutation of S203 renders BRF1 insensitive to PKB and 
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MK2 mediated inhibition in cotransfection ActD-chase experiments 
and, therefore, seems to play a role in regulation of BRF1 activity. 
Another way to control the activity of AUBPs is the regulation of 
their localization in the cell. Therefore, in a third part, the question 
was addressed, where the AUBPs HuR, AUF1
p37
, BRF1 and TTP are 
localized in the cell and whether their localization might play a role 
in regulating the activity of these proteins. The effects of activated 
signaling cascades, known to stabilize ARE-mRNA, on AUBP 
localization were investigated. In the case of p38 MAPK and PI3-K 
stabilization of ARE-mRNA is, indeed, accompanied by translocation 
of the stabilizing AUBPs HuR and AUF1
p37
 to the cytoplasm. 
Surprisingly, PKB, a downstream kinase of PI3-K, does not affect 
HuR and AUF1
p37
 localization, indicating that PI3-K regulates their 
localization via another pathway. Probably, the effect is mediated via 
PKC, as stimulation by TPA, a potent activator of PKC, does also lead 
to cytoplasmic accumulation of HuR and AUF1
p37
. In addition, HuR 
localization alters early during mitosis. At the onset of prophase, HuR 
is exported to the cytoplasm, indicating, that HuR might play a role in 
mitosis.
In the case of BRF1 and TTP no changes in localization could be 
observed in response to external stimuli. These two proteins are 
equally distributed in the cell, indicating that nuclear storage of these 
proteins cannot account for their inactivation.
To shed light on the physiological role of BRF1, a cell line was 
constructed with doxycycline-repressible BRF1 expression. This line 
was used in the last part of this thesis, to investigate, whether BRF1 
plays a role in cell cycle control. Overexpression of BRF1 did accelerate 
progression of serum starved mouse fi broblast cells from G0/G1 phase 
to S phase. Downregulation of BRF1 by siRNA, on the other hand, did 
have the opposite effect. However, the effect was reproducible but only 
marginal. Therefore, the project was discontinued at this stage.
Taken together, the data presented gives insight into the mechanisms, 
linking extracellular signaling to mRNA stability. For BRF1 two sites 
of regulation, namely S92 and S203 could be identifi ed. Further, 
export of the two stabilizing AUBPs HuR and AUF1
p37
 seems to play 
an important role in ARE-mRNA stability control. A dual role could be 
assigned to the PI3-K signaling pathway: PI3-K inactivates the ARE-
mRNA destabilizing protein BRF1 by PKB mediated phosphorylation 
at S92 and, via a PKB independent pathway, PI3-K exports HuR from 
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Posttranscriptional Regulation of Gene Expression by Degradation of 
Messenger RNA
The fl ow of genetic information from DNA to protein is highly regulated at multiple stages. In 
addition to the well-studied control at the level of transcription and translation, the turnover of 
messenger RNA (mRNA) plays a crucial role in determining the amount of a given protein to be 
synthesized. The sum of mRNA synthesis and degradation affects both, the amount of protein that 
can be synthesized with a given translation rate and also the duration of translation. By transiently 
stabilizing short lived transcripts, steady state mRNA levels can be effi ciently elevated within 
precisely controlled time windows, without changing the rate of transcription (Ross, 1995). This 
mechanism is used in many cases to quickly adapt the cells to stress signals, as for example 
in macrophages stimulated by IL-1 where increased cytokine production occurs (Huang et al., 
2000; Tebo et al., 2000). Figure 1 shows, how mRNA levels change, if transcription is considered 
independent of the RNA concentration and degradation follows fi rst order kinetics (dependent on the 
concentration of the substrate) (Hargrove et al., 1989): With a constant transcription rate high levels 
of slow decaying mRNA accumulate. These levels remain high for a long time after transcription 
is turned off (panel A). If the mRNA is rapidly turned over, less message can accumulate, but the 
steady state is reached more quickly (compare panel A and B). Upon transcription stop, mRNA with 
a rapid decay disappears very quickly. By changing the stability of mRNA, high levels of mRNA 











Figure 1: Levels of slowly (A) or rapidly decaying mRNA (B) in arbitrary units plotted against time. At the dotted line 




When messenger RNA was discovered more than 40 years ago in E.coli, one of its main properties 
was instability, as seen by pulse labeling (Brenner et al., 1961; Gros et al., 1961). Half-lives of 
mRNAs range from 30 seconds to 20 minutes in E. coli. In eukaryotes mRNA turnover is slower, but 
half-lives are still usually shorter than generation time ranging from 20 minutes to over 24h. To assure 
proper function of the newly transcribed RNA, it is routed through many mRNA-protein complexes 
that mediate splicing, polyadenylation, capping, nuclear export, translation and fi nally degradation. 
Aberrant RNA needs to be detected and degraded. These processes have to be controlled tightly in a 
way that every RNA meets its proper fate. How does a cell distinguish between RNA that has to be 
processed and RNA that has to be degraded completely? In the last few years, substantial progress 
has been made in understanding, how these processes work and which enzymes are involved. 
Interestingly, it has been found that the same or at least similar enzyme-complexes are responsible 
for RNA processing, maturation and degradation.
In Prokaryotes
In bacteria, mRNA degradation appears to be initiated by one or more endonucleolytic cleavages. 
This step is followed by 3’-5’ exonucleolytic digestion of the resulting mRNA fragments. Three 
endoribonucleases and three 3’-5’ exoribonucleases have been identifi ed in bacteria. The major 
endonucleolytic enzyme in mRNA decay is RNase E (Rne). Apart from its function in mRNA 
degradation it also plays a role in processing the 9S ribosomal RNA (rRNA) to the 5S form. 
RNase E cleaves single stranded mRNA at specifi c sites typically in an AU-rich context. 
Interestingly, a free 5’-end enhances the activity of RNase E (Bouvet and Belasco, 1992), indicating 
that determinants at the 5’-end of mRNAs regulate its susceptibility to endonucleolytic cleavage. 
As cleavage by RNase E again produces free 5’ monophosphates, further cleavage of the remaining 
fragments is accelerated by the new free 5’-ends and degradation, therefore, seems to processes in a 
5’-3’ direction. Another ribonuclease with overlapping specifi city to RNase E is RNase G. The third 
endonuclease, RNase III, cleaves double strand regions of mRNA. 
The exonucleases responsible for RNA decay include the hydrolytic RNase II and polynucleotide 
phosphorylase (PNPase), a phosphorolytic enzyme from the RNase PH family of exonucleases 
and oligoribonucleases, which is required for the breakdown of small 2-5 nucleotide fragments. 
Secondary structures on mRNA impede proper RNA degradation by RNase II and PNPase. 
However, the discovery of a multiprotein-complex termed the degradosome during purifi cation of 
RNase E (Ehretsmann et al., 1992; Carpousis et al., 1994; Py et al., 1994; Carpousis et al., 2001) 
provided a satisfactory solution to this problem. The key mRNA decay RNases in E.coli, RNase E 
and PNPase, are associated together with the DEAD-box containing ATP-dependent helicase RhIB 
in this complex (Py et al., 1996), which is able to unwind stable secondary structures, making the 
RNA accessible to the combined action of endo- and exoribonucleases. Other components are also 
found in the degradosome, for which no function has been assigned yet. Apart from RNA decay, the 
degradosome is also involved in processing 9S to 5S rRNA.
An additional important enzyme in mRNA degradation is the poly(A)polymerase PAP. It has been 
found to polyadenylate prokaryotic RNA at their 3’-end. Poly(A) tails typically range from 10 - 40 
nucleotides and have been found to decrease the half-lives of mRNAs. This has been explained 
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by a model, where extension of a RNA 3’-end by the addition of a poly(A) tail facilitates binding 
of RNase II and PNPase, which is inhibited by double stranded secondary structures, thereby 
enhancing exonucleolytic degradation. Further details of prokaryotic mRNA turnover are reviewed 
in (Steege, 2000; Carpousis, 2002).
In Eukaryotes 
In yeast mRNA decay is initiated by removal of the poly(A)-tail. Two distinct deadenylation activities 
were found: The poly(A)-nuclease (Pan2/3) complex trims nascent poly(A)-tails in the nucleus and 
the cytoplasm and Ccr4 (Carbon catabolite repression 4) / Caf1 (Ccr4 associated factor 1), which 
have previously been defi ned as transcriptional regulators, are required for optimal deadenylation. 
The dual role of Ccr4/Caf1 in deadenylation and transcription points to a coupled regulation of these 
two processes. 
After deadenylation the 5’ cap of mRNA is removed. Several factors have been identifi ed, which are 
involved in this process, including Dcp1/2, Vps16, Pat1 and the Lsm proteins. After decapping, the 
mRNA body is degraded by the 5’ exonuclease Xrn1 (for review see (Wilusz et al., 2001)). Figure 2 
shows an overview of the mRNA degradation pathways present in eukaryotes.
Although decay in yeast is mainly directed 5’-3’, there is 3’-5’ exonuclease activity present. Similar 
to the proteasome responsible for the degradation of proteins and the degradosome in bacteria 
described in the previous chapter, a multiprotein complex named the exosome was found to exert 
this function (Mitchell et al., 1996; Mitchell et al., 1997; Allmang et al., 1999b). The exosome 
contains 3’-5’ exonucleases. It has been found to trim 5,8S rRNA (Mitchell et al., 1996), small 
nucleolar RNA (snoRNA), small nuclear RNA (snRNA) (Allmang et al., 1999a) and to degrade 
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Figure 2: Summary of eukaryotic mRNA turnover. Adapted from (Parker and Song, 2004).
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mRNA in an ATP-dependent manner from the 3’-end (Anderson and Parker, 1998). In yeast, the 
exosome consists of at least 11 different proteins, 10 of which are 3’-5’ exonucleases (table 1). Six 
proteins of the complex are 3’-5’ phosphorolytic enzymes related to the E.coli RNase PH (Rrp41p 
(for ribosomal RNA processing 41 protein), 42p, 43p, 45p, 46p and Mtr3p), Rrp44 is a hydrolytic 
enzyme related to RNase II in E.coli and the other components (Rrp4p, 40p and Csl4p) have a 
S1 RNA-binding domain. The fact that all these exosomal components are essential for viability 
(Mitchell et al., 1997) indicates that, in addition to their ribonucleolytic activity, they are also crucial 
for correct assembly of the complex. The exosome is present in the cytoplasm and the nucleus, 
where an additional 3’-5’ exoribonuclease (Rrp6p) forms part of the complex (Mitchell et al., 1997; 
Allmang et al., 1999b; Zanchin and Goldfarb, 1999). Although the structure of the exosome has not 
been resolved yet, based on homology of many exosomal components to the bacterial RNase PH, 
a ring like structure seems plausible, where the different nucleases surround the RNA (Symmons 
et al., 2002). For effi cient exosome function, associated factors are required. Ski2p and Mtr4p are 
helicases that disrupt secondary RNA structures and protein-RNA interactions. In addition, they 
seem to deliver the RNA to the exosome. The interaction of these proteins with the exosome may 
be direct or through binding of Ski3p and Ski8p, two proteins required for mRNA degradation 
(Anderson and Parker, 1998).
Similar to yeast, deadenylation is also the fi rst step of the major mRNA decay pathway in mammalian 
cells. The poly(A)-ribonuclease (PARN/DAN) is the poly(A)-specifi c deadenylating nuclease 
in mammalian cells and X. leavis oocytes (Korner and Wahle, 1997; Korner et al., 1998). The 
subsequent steps of mRNA decay in mammalian cells are poorly defi ned. Decapping may occur after 
deadenylation, followed by 3’-5’ exonucleolytic digestion of the mRNA body. 5’ exonucleases have 
also been identifi ed in mammalian cells, suggesting bidirectional degradation, however, in vivo 3’-5’ 
degradation was found to be the major pathway (Mukherjee et al., 2002). In humans, an exosome 
complex has been purifi ed as well. The human homolog of Rrp4p (hRrp4p) was found to be in a 
complex in HeLa cells, comparable to the yeast exosome (Mitchell et al., 1997). hRrp4p associates 
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Table 1: The table shows the exosomal components in yeast and human and their homologs in E. coli. 
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with PM-Scl100 and PM-Scl75, which are components of the PM-Scl particles (Allmang et al., 
1999b), recognized by the autoimmune sera of patients suffering from Polymyositis-scleroderma 
overlap syndrome. The PM-Scl particles turned out to be the human counterpart of the yeast 
exosome. It contains 11-16 proteins, 10 of which are homologs to the yeast exosome subunits. The 
human exosome is located in the cytoplasm and the nucleus, with one component (PM-Scl100) only 
present in the nuclear complex. Four of the human proteins (hRrp4p, 41p, 44p and Csl4) have been 
shown to suppress the growth defect of mutant yeast strains, lacking the functional yeast homolog 
(Mitchell et al., 1997; Allmang et al., 1999b). In addition to the exoribonucleases, helicases are also 
associated with the mammalian exosome (Tran et al., 2004).
For some mammalian mRNAs, (e.g. IGF-II, transferrin receptor, c-myc) endonucleolytic, 
deadenylation-independent cleavage has been reported (Beelman and Parker, 1995; Lemm and 
Ross, 2002) (See also Fig. 2). The resulting fragments are then further degraded in the 3’-5’ and the 
5’-3’ direction.
Comparing prokaryotic mRNA decay to the eukaryotic process, several striking features emerge: 
First, in eukaryotic cells the 5’-3’ decay pathway can be found in addition to the evolutionary 
conserved 3’-5’ degradation pathway. Second, the poly(A) tails in prokaryotes and eukaryotes have 
an opposite function. Whereas in eukaryotes the poly(A) tail protects mRNA from degradation, in 
prokaryotes it destabilizes the RNA. Interestingly in both, prokaryotes and eukaryotes, a multiprotein 
complex, consisting mainly of exoribonucleases, is responsible for the 3’-5’ degradation of mRNA. 
Why these enzyme-complexes are formed is not clear yet. Probably, the high concentration of 
ribonucleases and helicases assures higher effi ciency of mRNA degradation. Maybe several different 
ribonucleases perform distinct steps in processing or degrading mRNA, reducing the amount of free 
premature end products.
Another mechanism of mRNA degradation was discovered in 1979. It was found that nonsense 
mutations in eukaryotic mRNA creating a premature termination codon (PTC) rendered the message 
unstable due to the so-called nonsense-mediated decay (NMD) (Chang et al., 1979; Losson and 
Lacroute, 1979). After splicing, proteins are deposited at the exon-exon junctions, known as the 
exon junction complex (EJC). It is thought that, in mammals, these factors are not only required for 
proper mRNA splicing and export, but serve also as markers. These markers are removed by the 
ribosome during the fi rst round of translation. As introns are normally only present in the coding 
region, any termination codon placed upstream of an EJC is defi ned as premature and is recognized 
by the “surveillance complex” containing the Upf proteins. Subsequent degradation is thought 
to occur via deadenylation-independent decapping followed by 5’-3’ exonucleolytic degradation 
(see Fig. 2). In the fruit fl y the EJC is dispensable for NMD, indicating that PTC-recognition 
occurs independently of the exon boundaries (Gatfi eld et al., 2003). Further, Gatfi eld showed 
that in drosophila NMD is initiated by endonucleolytic cleavage (Gatfi eld and Izaurralde, 2004). 
NMD reduces the amount of putatively harmful, aberrant proteins to be synthesized. Interestingly, 
inactivation of the NMD pathway has also been shown to affect levels of a variety of “normal” 
(none PTC-containing) mRNA, indicating that not only aberrant mRNA decays via this pathway 
(reviewed in (McKendrick, 2003)).
Recently, a process named nonstop decay was discovered, where the absence of a stop codon is 
detected by the cell and leads to targeted degradation of the aberrant message (Frischmeyer et al., 
2002). The degradation of the mRNA lacking a stop codon requires the exosome complex (van Hoof 
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et al., 2002) and two additional associated factors, namely the Ski complex (consisting of Ski2p, 
Ski3p and Ski8p) and Ski7p. It is thought that the ribosome translates through the poly(A) tail and 
stalls at the 3’-end. Ski7p binds to the empty A-site of the ribosome and recruits the Ski complex 
together with the exosome to degrade the mRNA.
To defend an organism against exogenous (viruses) or endogenous (transposons) mobile genetic 
elements and as a mechanism to regulate gene expression, cells have developed an additional RNA 
degrading pathway. The process called RNA interference (RNAi) was fi rst discovered in plants and 
subsequently found to be present in C. elegans, D. melanogaster and mammals. Double stranded 
RNA (dsRNA) is processed into small 21-25nt RNA fragments by Dicer, an evolutionary conserved 
RNase III family member. The small inhibitory RNAs (siRNAs) fragments guide a nuclease 
containing protein complex named RISC (for RNAi-induced silencing complex) to homologous 
substrate mRNA through base-pairing of the antisense strand of the siRNA. Subsequently, the 
targeted mRNA is degraded. (See reviews (Tijsterman et al., 2002; Denli and Hannon, 2003) and 
references therein for more detailed information). In recent years RNAi has become a powerful tool 
in research to transiently knock down gene expression. Hairpin RNAs expressed from inducible 
promoters (e.g. tet-controlled promoter) are also processed into siRNA by Dicer and allow spatio-
temporal controlled RNAi (Elbashir et al., 2001; Brummelkamp et al., 2002).
cis-Determinants of mRNA Stability
Many short-lived transcripts carry cis-elements that regulate their stability probably by controlling 
the access of the mRNA to the decay machinery. These elements are found all over the RNA as 
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A major cis-element is the so-called AU-rich element (ARE), which is located in the 3’ untranslated 
region (3’UTR) of many short-lived transcripts from cytokines, proto-oncogenes, growth factors or 
cell cycle regulators (Shaw and Kamen, 1986; Chen and Shyu, 1995). A human database by Bakheet 
and coworkers revealed that 8% of all mRNAs, encoding a diverse functional repertoire of proteins, 
contain AREs (Bakheet et al., 2001/ http://rc.kfshrc.edu.sa/ared). A recent statistical analysis by 
An et al. reported that AREs derive from the poly(T) regions complementary to Alu-repeats (An et 
al., 2004). A general feature of these elements is a variable number of, often overlapping, AUUUA 
motifs, frequently placed in an U-rich context (class I and II according to Chen et al. (Chen and 
Shyu, 1995)). Another class of AREs (class III) (Peng et al., 1996) lacks the AUUUA pentamer 
but is characterized by a U-rich region. However, in recent years this classifi cation has declined in 
importance, as it turned out that the structural differences of these three classes did not necessarily 
translate into functional differences. KSRP, for instance, promotes decay of mRNAs containing 
AREs of either of the three classes (Gherzi et al., 2004). In addition to the AUUUA motif, auxiliary 
domains seem to be important for the destabilizing activity of AREs (Winzen et al., 2004). The 
ARE functions by targeting mRNA for rapid degradation. The functionality of this element was 
discovered by Shaw and Kamen, who introduced the ARE of GM-CSF into an α-globin reporter 
transcript, thereby destabilizing this message (Shaw and Kamen, 1986). Similar action has been 
reported for numerous AREs by mutational analysis e.g. for c-myc (Jones and Cole, 1987), c-fos
(Shyu et al., 1989), c-jun (Peng et al., 1996), IL-3 (Hirsch et al., 1995) or tumor necrosis factor α 
(TNFα) (Xu et al., 1997).
AREs promote decapping (Gao et al., 2001) and deadenylation followed by degradation of the 
mRNA body (Shyu et al., 1991; Xu et al., 1997) via the exosome (Chen et al., 2001; Mukherjee et 
al., 2002). Stabilization of short-lived ARE-containing transcripts by exogenous signals leads to a 
rapid accumulation of mRNA with a consequent increase of protein levels. Physiological examples 
are found in T-cells activated by immune stimulation (Lindsten et al., 1989), mast cells responding 
to IgE-linked allergens (Wodnar-Filipowicz et al., 1989; Wodnar-Filipowicz and Moroni, 1990), or 
macrophages stimulated by IL-1/TNFα (Huang et al., 2000), where increased cytokine production 
occurs. Deregulated ARE-dependent mRNA turnover can contribute to oncogenic transformation 
(Schuler and Cole, 1988; Nair et al., 1994; Stoecklin et al., 2003a), infl ammation (Carballo et al., 
1998) and immunopathology (Kontoyiannis et al., 1999), underlining the physiological relevance 
of this process. In addition to mRNA turnover, the ARE has been reported to regulate translation 
of TNFα mRNA (Kontoyiannis et al., 1999; Piecyk et al., 2000). As discussed below, the ARE is 
recognized by AU-binding proteins, which seem to be the key players, regulating the stability of 
ARE-containing message.
Iron Responsive Element (IRE)
This stem loop structure (23-27 bases in length) is present in the 3’UTR of transferrin receptor (TfR) 
mRNA and in the 5’UTR of ferritin mRNA. The transferrin receptor imports iron into cells and 
ferritin is a major intracellular iron-storage protein. At low iron levels, two iron regulatory proteins 
(IRP1/2) bind to the IRE of TfR mRNA, thereby stabilizing this transcript and allowing more iron 
uptake. Binding of IRP1/2 to the 5’ UTR of ferritin mRNA, on the other hand, blocks translation and 




A C-rich stretch is found in the α-globin transcript. It was shown to be bound by the so-called 
α-complex consisting of α-CP1, α-CP2 and AUF1 (Wang et al., 1995; Kiledjian et al., 1997). The 
α-CP proteins interact with the poly(A) binding protein (PABP), enhancing its binding effi ciency 
to the 3’UTR of α-globin. This RNA dependent interaction stabilizes mRNA by protecting it from 
deadenylation-dependent degradation (Wang et al., 1999; Wang and Kiledjian, 2000). 
Constitutive Decay Element (CDE)
Another decay promoting element in the 3’UTR of TNFα has been characterized in our group 
(Stoecklin et al., 2003b). The CDE mediates decay of the message when transferred into an 
β-globin reporter construct. This decay is, in contrast to the ARE-mediated decay, not abrogated by 
lipopolysaccharide (LPS)-treatment in RAW 264.7 cells or by activation of p38 MAPK or PI3-K in 
NIH3T3 cells; therefore the element was named constitutive decay element. So far, no consensus 
motif has been characterized for the CDE and it is not known whether a similar element is present 
in other transcripts. Recent work in our lab (Bernd Rattenbacher, unpublished data) showed, that 
nucleolin interacts with the CDE and may be involved in destabilizing the TNFα message.
Histone 3’ Terminal Stem Loop
Histone mRNAs lack a poly(A)-tail but have a 3’ terminal stem loop motif (6bp stem and a 4bp 
loop) (Pandey and Marzluff, 1987), which mediates the cell cycle dependent decay via a stem loop 
binding protein (Whitfi eld et al., 2000). Interestingly, histone proteins promote degradation of its 
own mRNA in an in vitro decay assay, but not of other mRNA, such as c-myc or γ-globin (Peltz and 
Ross, 1987).
Insulin-Like Growth Factor II (IGF-II) Stem Loop
Human IGF-II mRNA is subjected to site-specifi c endonucleolytic cleavage in the 3’ untranslated 
region. This is the fi rst and rate-limiting step in degradation of this message. Scheper et al. have 
identifi ed a conserved stable double-stranded RNA stem structure that is essential for cleavage 
(Scheper et al., 1995). Not only the double-stranded character but also the sequence of the stem 
is important for effi cient cleavage. Although van Dijk and coworkers have identifi ed a protein 
interacting with this structure (van Dijk et al., 1998), no follow-up publications confi rmed its role in 
cleavage of IGF-II mRNA and the mechanism of this cleavage is still unknown.
Coding Region
mRNAs from c-fos, c-myc and β-tubulin contain instability elements within their coding region. 
The mCRD (for major coding region determinant) in c-fos is a purine-rich 320-nucleotide motif 
that renders the mRNA unstable. It encodes for a leucine zipper, crucial for c-fos protein function. 
A complex of proteins, including AUF1 isoform p37, poly(A)-binding protein (PABP), PABP-
interacting protein (PAIP) and Unr, a purine-rich, RNA binding protein, binds to the mCRD (Grosset 
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et al., 2000). These fi ndings implicate an interaction between the poly(A)-tail and the mCRD. 
However, the mechanism by which mCRD mediates degradation is not known yet.
β-tubulin mRNA stability is affected by the fi rst 13 translated nucleotides. mRNA turnover in this 
case is translation dependent, as the fi rst four translated amino acids display the recognition sequence 
conferring instability to the ribosome-bound mRNA (Gay et al., 1987; Yen et al., 1988).
Coding sequences in exon 2 and 3 of c-myc are important for downregulation of the transcript during 
myoblast differentiation (Yeilding and Lee, 1997). A protein specifi cally binding to these sequences 
and protecting c-myc mRNA from endonucleolytic cleavage has been identifi ed (CRD-BP for CRD 
binding protein) (Prokipcak et al., 1994). Evidence exists that translational pausing generates a 
ribosome-defi cient region downstream of the pause site, and this region is exposed to endonuclease 
attack unless it is shielded by the CRD-BP (Lemm and Ross, 2002).
5’ Untranslated Region (5’ UTR)
The 5’ UTR cannot only regulate translation rate of a given transcript, but also the stability in a 
translation-dependent or independent manner. Studies by Chen et al. (Chen et al., 2000) and Tebo et 
al. (Tebo et al., 2000) have identifi ed stabilizing elements in the 5’UTR of IL-2 and the chemokine 
KC mRNA. In the case of IL-2, a JNK-response element (JRE) stabilizes IL-2 message upon T-cell 
activation. YB-1 and nucleolin bind specifi cally to this element and seem to exert this effect.
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AU-rich Element Binding Proteins (AUBPs)
Over the past few years several ARE-binding proteins (AUBPs) affecting mRNA turnover have 
been identifi ed. Among these proteins we fi nd stabilizing (HuR) or destabilizing (BRF1, BRF2, 
TTP, KSRP) proteins. None of those proteins have been shown to be enzymatically active. They 
rather seem to protect the RNA from the decay machinery (stabilizing factors) or to target the RNA 
for degradation. A summary of the currently known AUBPs is shown in table 3.
HuR (HuA)
HuR was originally identifi ed in D. melanogaster as an essential factor for neural development 
(Campos et al., 1985). It is a ubiquitously expressed member of the embryonic lethal abnormal vision 
(ELAV) family of RNA-binding proteins (Good, 1995; Ma et al., 1996). By gel shift (Myer et al., 
1997) and UV-crosslinking experiments (Fan et al., 1997), HuR has been shown to bind to a variety 
of ARE-mRNA, including the ones from IL-3 and c-fos (Ma et al., 1996). Overexpression (Peng et 
al., 1998; Fan and Steitz, 1998a; Ming et al., 2001; Chen et al., 2002), antisense RNA (Wang et al., 
2000a; Wang et al., 2000b) and RNAi (Raineri et al., 2004) experiments later suggested a role for 
HuR in stabilizing ARE-containing mRNA, possibly by binding to AREs (mainly class I and II) and 
protecting the message from degradation.
HuR, as well as the other Hu-family proteins, contains three classical RNA recognition motifs 
(RRMs). Deletion of the third of these RRMs, which has been suggested to bind the poly(A)-tail 
(Ma et al., 1997), abolishes HuRs ability to stabilize ARE-containing mRNA (Fan and Steitz, 
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Table 3: AU-rich element Binding Proteins
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1998a). Between RRM2 and 3 there is a nucleo-cytoplasmic shuttling sequence (HNS for HuR 
nucleo-cytoplasmic shuttling sequence) (Fan and Steitz, 1998b) similar to the M9 domain in 
hnRNP A1. Increased cytoplasmic localization of the predominantly nuclear HuR correlates with 
stabilization of ARE-containing mRNA: e.g. stabilization of p21 (Wang et al., 2000b) and RhoB 
message (Westmark et al., 2004) upon UV irradiation or cyclin A and B1 stabilization in late G1/S 
and G2 phase of the cell cycle (Wang et al., 2000a) is accompanied by accumulation of HuR in the 
cytoplasm. Also heat shock, a stress known to stabilize ARE-mRNA (Laroia et al., 1999), leads to 
increased cytoplasmic localization of HuR (Gallouzi et al., 2000). It is thought that HuR escorts the 
mRNA out of the nucleus, thereby increasing its stability (Fan and Steitz, 1998a; Fan and Steitz, 
1998b).
Four HuR-interacting proteins have been identifi ed (Brennan et al., 2000): SETα/β (von Lindern 
et al., 1992; Matsumoto et al., 1993;), pp32 (Malek et al., 1990) and APRIL (Mencinger et al., 
1998). These proteins bind to the RRM3. Three of these binding partners (SETα/β  and pp32) have 
previously been identifi ed as phosphatase 2A (PP2A) inhibitors (Li et al., 1996; Saito et al., 1999), 
suggesting that PP2A is involved in regulating ARE-containing mRNA decay. pp32 and APRIL 
shuttle between the nucleus and cytoplasm, as shown by heterokaryon fusion experiments and 
interact with the nuclear export factor CRM1. These proteins, therefore, seem to be involved in 
modulating HuR export. In human colon cancer cells (Dixon et al., 2001) and tumors of the central 
nervous system (Nabors et al., 2001) HuR overexpression was detected, which could account 
for the increased stability of ARE-containing COX2, VEGF and IL-8 mRNA in these cells. Two 
independent reports claim a role of HuR in muscle differentiation. Overexpression of HuR in mouse 
embryonic muscle cells stabilizes two myogenesis-specifi c transcription factors (myogenin and 
MyoD) and drives differentiation of these cells (Figueroa et al., 2003), whereas RNAi against HuR 
has the opposite effect (van der Giessen et al., 2003).
AU-Binding Factor1 (AUF1/ hnRNP D)
AUF1 was fi rst identifi ed by Brewer and coworkers as a promoter of ARE-mRNA decay in K562 cells 
(Brewer, 1991). Although recombinant AUF1 lacked decay promoting activity in early experiments 
(Zhang et al., 1993), later work showed that increased expression of AUF1 is associated with rapid 
decay of ARE-mRNA in peripheral blood mononuclear cells (PBMCs) (Buzby et al., 1996; Buzby 
et al., 1999), smooth muscle cells (Pende et al., 1996) and monocytes (Sirenko et al., 1997).
AUF1 exists as four different isoforms, arising from alternative splicing: A 37 kDa core protein 
(p37), p40 containing an additional N-terminal insertion (exon 2), p42 with a C-terminal insertion 
(exon 7) and p45, containing exon 2 and 7. The presence of exon 7 (in p42 and p45) shifts the 
nucleo-cytoplasmic distribution of the protein to the nucleus and it blocks ubiquitination, whereas 





 correlates with rapid decay of ARE-containing mRNA, 
indicating that these two isoforms are mRNA stabilizing components (Laroia et al., 1999; Laroia et 
al., 2002; Laroia and Schneider, 2002). The absence of exon 2 (p37, p42) has been associated with 
high affi nity ARE-binding (DeMaria et al., 1997). Forced expression of p37 and p42 antagonizes 
ARE-mRNA stabilization, accompanying hemin-induced erythroid differentiation of K562 cells 
(Lofl in et al., 1999). On the other hand, overexpression of all four isoforms in 3T3 cells stabilizes 
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ARE-message (Xu et al., 2001). The precise role of AUF1 in ARE-mRNA turnover is still a matter 
of debate, however, the emerging models assign stabilizing and destabilizing roles to the different 
isoforms depending on the cell type, the cellular environment and the type of ARE (Xu et al., 
2001; Raineri et al., 2004). AUF1 seems to regulate mRNA stability by changing the structure of 
the RNA in response to signaling pathways. AUF1
p40
 has been reported to keep the bound mRNA 
in a condensed conformation, which changes upon phosphorylation of S83 and S87 (Wilson et al., 
2003a; Wilson et al., 2003b). 
In addition to the role of AUF1 in ARE-mRNA turnover, these proteins have also been shown to 
be part of the α-globin mRNA stability complex (Kiledjian et al., 1997) and to play a role in the 
mRNA decay directed by the c-fos mCRD (Grosset et al., 2000). Furthermore, AUF1 is involved in 
telomere maintenance (Eversole and Maizels, 2000) and transcriptional activation (Fuentes-Panana 
et al., 2000).
Tis11 Family
The Tis11 (Tetradecanoyl phorbol acetate (TPA)-induced sequence 11) family of proteins consists 
of 3 members in mammals: Tristetraprolin (TTP), Butyrate response factor 1 (BRF1) and 2 (BRF2), 
(encoded by Zinc fi nger protein 36 (Zfp36), Zfp36 like 1 (Zfp36L1) and Zfp36L2 respectively). A 






-H zinc fi nger motifs, each 
preceded by a conserved YKTEL sequence (Varnum et al., 1991; Amann et al., 2003; Michel et al., 
2003; Hudson et al., 2004). All Tis11 family members bind to the ARE of TNFα (Lai et al., 2000). 
Two homologs of this family were cloned in yeast (Thompson et al., 1996) and in frog and fi sh a 
fourth family member has been found (De et al., 1999). 
Tristetraprolin (TTP/ Tis11/ Zfp36p/ NUP475/ GOS24)
TTP was found independently by three different groups: Herschman and colleagues identifi ed 
a partial clone of the cDNA in a screen for phorbol-ester-responsive genes and named it Tis11 
(Varnum et al., 1989). DuBois et al. cloned TTP under the name of NUP475 (nuclear protein 475) 
as a serum-induced gene (DuBois et al., 1990), and the Blackshear lab found it in a screen for 
genes that are rapidly turned on at the transcriptional level in response to insulin (Lai et al., 1990). 
Due to the presence of three characteristic P-P-P-P-G motifs, Blackshear and coworkers named the 
protein Tristetraprolin (TTP). Apart from TPA, serum and insulin, TTP mRNA expression was later 
shown to be induced with similar kinetics by a variety of growth factors (EGF, FGF), by LPS and 
by TNFα (Carballo et al., 1998; Fairhurst et al., 2003). Several years after cloning, the function of 
TTP came apparent, when TTP knockout mice were generated (Taylor et al., 1996). TTP (-/-) mice 
are born normal, but, within a few months, develop a phenotype characterized by loss of weight, 
severe polyarticular erosive arthritis and myeloid hyperplasia in and outside of the bone marrow. 
They also developed alopecia, dermatitis, conjunctivitis and autoimmunity. The observed phenotype 
resembled the one induced by chronic administration of TNFα (Keffer et al., 1991; Ulich et al., 
1993). Injection of a monoclonal antibody against TNFα could suppress this phenotype (Taylor et 
al., 1996), indicating that the phenotype arises due to TNFα overproduction. Indeed, macrophages 
from TTP (-/-) mice exhibit increased TNFα and GM-CSF mRNA stability (Lai et al., 2000), which 
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Fig. 4: A: Phylogenetic tree of the known Tis11 family members. B: Alignment of the zinc fi nger regions of the Tis11 




could explain the TNFα overproduction in the knockout mice. Further investigations revealed that 
TTP can bind to the ARE of TNFα mRNA dependent on the two zinc fi ngers (Lai et al., 1999), 
thereby destabilizing the message (Carballo et al., 1998). The 77 amino acids surrounding the two 
zinc fi ngers are suffi cient for deadenylation and decay induction (Nakielny and Dreyfuss, 1996). 
Recently, it has been shown independently by Brooks et al. and Tchen et al. (Brooks et al., 2004; 
Tchen et al., 2004) that TTP binds to its own 3’ UTR and destabilizes its mRNA. This provides 
a negative feedback loop, controlling the levels of TTP. In our lab, TTP was found to reverse the 
mutant phenotype of the ARE-decay defective slowC cells lacking BRF1 expression (Stoecklin et 
al., 2000). It was found that TTP promotes deadenylation of ARE-mRNA in vitro (Lai et al., 2003) 
and in vivo (Lai et al., 1999). Interestingly, deadenylation is not the only way, how TTP affects 
stability of ARE-mRNA, as the poly(A)-tail in GM-CSF, TNFα or IL-3 is not required for TTP 
mediated mRNA turnover (Lai and Blackshear, 2001). The fact that non-RNA-binding TTP inhibits 
degradation of ARE-mRNA suggests that TTP function requires interacting proteins (Lai et al., 
2002). Indeed, Chen and coworkers could show that TTP promotes degradation of ARE-mRNA by 
recruiting the exosomal decay machinery (Chen et al., 2001). 
TTP is a nucleo-cytoplasmic shuttling protein containing a nuclear localization signal (NLS) between 
amino acids 76-189 and a leucine-rich nuclear export signal (NES) in its N-terminus (Murata et al., 
2002; Phillips et al., 2002). In yeast, overexpression of the two zinc fi nger protein family members 
(CTH1/2) or mammalian TTP causes delayed entry of cells into exponential growth, depending on 
the zinc fi ngers (Thompson et al., 1996). In mammalian cells continuous TTP expression causes 
apoptotic cell death and sensitizes cells to TNFα-induced apoptosis (Johnson et al., 2000; Johnson 
et al. 2002). In addition to its decay promoting activity, TTP was also found to exert a suppressive 
effect on the promoter of TNFα and IL-8, which is released by p38 activation (Zhu et al., 2001). 
Butyrate Response Factor 1 (BRF1/ Tis11b/ Zfp36L1p/ Berg36/ ERF1/ cMG1)
BRF1 was originally cloned as an epidermal growth factor (EGF)-inducible gene in rat intestinal 
epithelial cells (Gomperts et al., 1990) and its human homolog was cloned four years later (Bustin 
et al., 1994). The human gene was mapped to chromosome 14q22-24 (Maclean et al., 1995). BRF1 
expression is induced by insulin, insulin-like growth factor 1 (IGF-1) (Corps and Brown, 1995) and 
by adrenocorticotropin (ATCH) (Chinn et al., 2002). BRF1 expression is suppressed by butyrate, 
in contrast to TTP, which is not affected (Maclean et al., 1998). Interestingly, sodium butyrate, a 
fermentation product of dietary fi ber, inhibits colorectal cancer cell proliferation by inducing growth 
arrest, differentiation and apoptosis. Unpublished work in our lab by Ines Raineri and co-workers 
showed that downregulation of BRF1 by siRNA in embryonic stem cells induces morphological 
changes similar to differentiation. It has also been found that high levels of BRF1 contribute to 
leukemogenesis mediated by the fusion transcription factor AML1-MTG8 (Shimada et al., 2000). 
Reduction of BRF1 levels could, therefore, be of benefi t for cancer patients. On the other hand, 
continuous expression of BRF1 causes apoptosis in 3T3 and HeLa cells, but has no effect on TNFα 
induced apoptosis (Johnson et al., 2000). Its physiological function in proliferation and apoptosis is 
therefore still a matter of debate. Recently it was shown that a BRF1 knockout is lethal at embryonic 
day 11 due to a defect in chorioallantoic fusion (Stumpo et al., 2004). 
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BRF1 exhibits CRM1 dependent nucleo-cytoplasmic shuttling (Phillips et al., 2002). It contains 
a NES in its C-terminus. BRF1 was identifi ed in our lab by a functional screen aimed at fi nding 
genes responsible for ARE-dependent decay (Stoecklin et al., 2002). A human fi brosarcoma cell 
line with frameshift mutations in both BRF1 alleles, therefore lacking BRF1 expression, was cloned 
(slowC). The slow ARE-mRNA degradation phenotype of this line could be reverted by transfection 
of BRF1. Further, BRF1 has been shown in a cell free system to stimulate deadenylation similar to 
TTP (Lai et al., 2003). 
Butyrate Response Factor 2 (BRF2/ Tis11d/ Zfp36L2/ ERF2)
BRF2 was cloned as the third member of the Tis11 protein family (Varnum et al., 1991). The 
human BRF2 gene was cloned by Nie et al., who claimed that it differs from its mouse homolog 
by encoding an additional 97 amino acids at its C-terminal end (Nie et al., 1995). This has later 
been shown to be wrong (De et al., 1999). BRF2 binds to and destabilizes TNFα mRNA (Lai et al., 
2000). The NMR structure of the BRF2 zinc fi ngers bound to a single stranded RNA oligonucleotide 
UUAUUUAUU was recently resolved by Hudson et al. (Hudson et al., 2004) and showed that 
each of the two similarly folded zinc fi ngers binds to separate UAUU sites (Figure 4C). As the zinc 
fi nger motive is highly conserved among the different Tis11 family members (Figure 4B) the same 
structural features are to be expected for TTP and BRF1. Recently, it was shown by Ramos and 
colleagues (Ramos et al., 2004) that partial BRF2 knockout mice lacking the fi rst exon of BRF2, 
but containing parts of the following intron, are viable. The only observed phenotype is infertility of 
the females. Fertilized embryos stop cell division at the two-cell state. Fertility could be restored by 
transplantation of wild-type ovaries.  
Similar to BRF1, BRF2 also contains a NES in its C-terminus and shuttles between the nucleus and 
cytoplasm in a CRM1 dependent fashion (Phillips et al., 2002).
KSRP (FBP2)
KSRP (K homology-type splicing regulatory protein) was originally identifi ed as a component 
involved in neuronal-specifi c c-src splicing (Min et al., 1997). It contains 4 copies of the RNA 
binding K homology (KH) domain. These domains are essential for the function of KH proteins 
in differentiation in fl ies, worms and mammals (Adinolfi  et al., 1999). KH proteins are important 
regulators of metabolic processes in prokaryotes and eukaryotes. KSRP is a ubiquitously expressed, 
shuttling protein and binds to TNFα and c-fos AREs. It has been shown to interact with the exosome 
and is thought to target ARE-mRNA for rapid degradation via this complex (Chen et al., 2001; 
Gherzi et al., 2004). 
CUGBP2 (NAPOR2/ ETR-3/ BRUNOL3)
CUGBP2 (CUG-binding protein2) is a prototype RNA binding protein of the CELF (CUGBP-ETR-
3-like factors) family. CELF proteins contain three RRMs, two of which are located as tandem repeats 
similar to HuR. However, apart from these motifs no homology can be found between CUGBP2 
and HuR (Choi et al., 1998). CUGBP2 is induced during apoptosis. It binds to CUG repeats (found 
in myotonic dystrophy (Lu et al., 1999)) and to the ARE of Cyclooxygenase-2 (COX-2). CUGBP2 
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expression is induced upon radiation. After binding to COX-2 mRNA, CUGBP2 stabilizes the 
message but inhibits its translation (Mukhopadhyay et al., 2003). In addition, CUGBP2 is involved 
in editing (Anant et al., 2001), splicing, and development of the central nervous system (Ladd et al., 
2001).
TIA-1, TIAR
TIA-1 (T-cell intracellular antigen-1) and TIAR (TIA-1 related protein) are RRM-containing 
proteins that bind specifi cally to the ARE of TNFα. Macrophages from mice lacking TIA-1 (TIA-
1 (-/-)) produce signifi cantly more TNFα protein than wild-type controls. However the half-life of 
TNFα transcripts is similar in wild type and TIA-1 (-/-) macrophages, indicating that TIA-1 does not 
regulate transcript stability but silences translation. Consistent with its role in translation, the absence 
of TIA-1 signifi cantly increases the proportion of TNFα transcripts that associate with polysomes 
(Gueydan et al., 1999; Piecyk et al., 2000). The translational inhibition of TIA-1 is specifi c for 
TNF-α, as GM-CSF and Interferon-α are not affected. The TIA proteins are nucleo-cytoplasmic 
shuttling proteins. In stressed cells they translocate from the nucleus into the cytoplasm, where they 
accumulate in subcellular sites called stress granules. In addition to the TIA proteins, eukaryotic 
initiation factors (eIF3, 4E, 4G), PABP, TTP, HuR and AUF1 are also found in these cytoplasmic 
structures, where translationally silenced mRNA is stored during stress (for review see (Kedersha 
and Anderson, 2002)).
PM-Scl75
A link between the exosome and ARE-mediated decay was provided by Mukherjee et al., who found 
that the exosomal component PM-Scl75, which is needed for effi cient 3’-5’ degradation, interacts 
with AREs (Mukherjee et al., 2002). This interaction could be responsible for targeting the exosome 
to ARE-containing short-lived message, facilitating its degradation.
Signal Transduction Pathways and their Involvement in ARE-mRNA 
Stability Control
A cell senses changing environmental conditions via a complex network of signaling cascades. The 
incoming stimuli are integrated into the appropriate response. Many pathways have been deciphered 
up to now and many have been found to regulate mRNA turnover. Stress stimuli, including UV-
exposure (Gorospe et al., 1998; Wang et al., 2000b), heat shock (Laroia et al., 1999) and hypoxia 
(Paulding and Czyzyk-Krzeska, 2000), can lead to stabilization of ARE-mRNA. AUBPs are obvious 
candidate targets for signaling pathways, regulating mRNA turnover. The signaling pathways 




Activation of receptor tyrosine kinases (RTKs) or G protein coupled receptors (GPCRs) can result 
in the recruitment of PI3-K to the plasma membrane. This interaction can also be indirect, via 
intermediate phospho-proteins, such as insulin receptor substrates (IRS1 or 2). PI3-K consists of 
a regulatory domain (p85), which associates via its src homology 2 (SH2) domain with the RTK 
(or the IRS), and a catalytic domain (p110), which catalyses the transfer of phosphate to the D-3 
position of the inositol ring of membrane localized phosphoinositides (PI). RTKs can also activate 
PI3-K indirectly via the small G-protein ras, which can bind the p110 subunit. The products of 





) act as signaling intermediates that regulate downstream signaling events. The 




 and, thereby, 
counteracts PI3-K signaling. Proteins containing pleckstrin homology (PH) domains are likely 
to bind to PtdIns(3,4,5)P
3
. Several cytoplasmic kinases contain a PH domain. Among them the 
protein kinase B (PKB)/AKT is the best-characterized downstream effector of PI3-K. Another PH 
domain containing kinase is PDK1, which phosphorylates and activates PKB and PKC (reviewed in 
(Vivanco and Sawyers, 2002)).
In our lab Ming et al. (Ming et al., 2001) have shown that transfection of an activated form of PI3-K 
stabilizes ARE-mRNA. This stabilization does not involve direct inactivation of TTP. Evidence is 
presented in this work and in (Schmidlin et al., 2004) that PI3-K mediated stabilization acts via 





































Fig. 5: Overview of the signal transduction pathways relevant to this work. Kinases are shown in green, small G-proteins 
in yellow, other factors in blue and the phosphate groups in red. Some of the most important biological responses of these 
pathways are mentioned. CM: Cell membrane.
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Protein Kinase B (PKB/AKT)
Since the cloning of PKB in the early nineties this protein kinase has emerged to play a central 
role in protein synthesis, transcription, cell growth, cell survival, angiogenesis and glycogen 
synthesis. It belongs to the AGC family of kinases together with the founding members PKA, PKG 
and PKC. PKB exists as three isoforms PKB α-γ (AKT1-3 respectively). It contains a N-terminal 
PH-domain, a central kinase domain and a C-terminal regulatory domain. Upon elevation of 
PtdIns(3,4,5)P
3
 levels by PI3-K, PKB is recruited to the membrane via its PH-domain. This causes 
unfolding of PKB followed by phosphorylation at threonine 308 (T308) and serine 473 (S473) by 
phosphoinositide-dependent kinase 1 (PDK1) and a yet unidentifi ed S473 kinase (S473K/PDK2). 
Phosphorylation of S473 is inhibited by tribble homologue 3 (TRB3) and C-terminal modulator 
protein (CTMP). Also PDK1 contains a PH domain, which mediates its membrane localization upon 
elevated PtdIns(3,4,5)P
3
 levels. Phosphorylation of PKB leads to its activation and translocation 
from the membrane (Figure 6). Many downstream targets of PKB (most of them sharing a R-X-R-
X-X-S/T-φ1 consensus motif) have been characterized. Among them we fi nd proteins like BAD, 
CREB, GSK3, mTOR, p21 or Raf. For reviews see also (Datta et al., 1999; Brazil and Hemmings, 
2001; Brazil et al., 2004). As already mentioned, evidence for a role of PKB in stabilization of ARE-
mRNA via inactivation of BRF1 has been published recently by our group (Schmidlin et al., 2004) 















































Fig. 6:  Overview on PKB signaling, adapted from (Brazil et al., 2004). Some of the most important biological responses 
of this pathway are mentioned.
1X: any amino acid/ φ:hydrophobic amino acid
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Protein Kinase C (PKC)
PKC also belongs to the AGC family of serine-threonine kinases. For activation, PKC needs to be 
phosphorylated by PDK1 resulting in an autophosphorylation step. PDK1 activity is regulated by 
PI3-K via the levels of PtdIns(3,4,5)P
3
 as described in the previous chapter. In the enzymatically 
competent (phosphorylated) state PKC is ready for activation by second messengers: The classical 
PKC isoforms are activated by calcium, diacylglycerol (DAG) and phospholipids, the novel isoforms 
by DAG and phospholipids, whereas the atypical isoforms can only be activated by phospholipids. 
A signaling cascade initiated by G-protein coupled receptors (GPCR) activates phospholipase C 
(PLC), which leads to the production of DAG, inositol-1,4,5-trisphosphate (IP
3
) and release of 
calcium. Phorbol-esters (e.g. TPA) are strong activators of some PKC isoforms, as they mimic 
the actions of DAG. Upon full activation PKC can then activate ERK1/2 and Raf. (reviewed in 
(Liebmann, 2001; Spitaler and Cantrell, 2004)). 
TPA is a potent stabilizer of ARE-mRNA, indicating that PKC is also involved in the control of 
mRNA turnover (Ming et al., 2001).
Small G-Protein ras
The ras genes were originally found in the 1960s as the transforming elements of the Harvey and 
Kirsten strains of rat sarcoma viruses. Later mutated alleles of cellular ras genes were identifi ed 
as dominant oncogenes in various human tumors. The mammalian ras family consists of three 
members. The H- and K-ras genes are the human homologs of viral genes and N-ras is derived from 
a human neuroblastoma cell line (reviewed in (Bar-Sagi, 2001)). Recently a ras like gene, expressed 
in embryonic stem cells, was cloned. This E-ras protein contains amino acids identical to the active 
mutants of ras and is oncogenic when transfected into 3T3 cells (Takahashi et al., 2003). The ras 
proteins are anchored to the plasma membrane via a farnesyl and/or palmitoyl modifi cation. ras 
exists in two forms: a GTP bound, active and a GDP bound, inactive form. Most stimuli activate ras 
by recruiting proteins that exchange GDP with GTP (so called GDP/GTP exchange factors (GEFs)) 
to the membrane associated ras protein. Activation of RTKs leads to recruitment of growth-factor-
receptor bound protein 2 (Grb2), serving as an adaptor protein for SOS (son of sevenless), the ras 
GEF. Three main classes of effector proteins are primarily stimulated by ras: Raf kinases (see ERK-
pathway), PI3-K (discussed above) and RalGEFs (reviewed in (Hilger et al., 2002)).
ras is a central player in many pathways and it has been shown that transfection of activated ras 
effi ciently stabilizes ARE-mRNA. This effect is dominant over any destabilizing function of BRF1 
or TTP (Sabrina Leuenberger, PhD thesis 2004).
Mitogen Activated Protein Kinase (MAPK) Pathways
MAPKs are evolutionary conserved enzymes, connecting extracellular signals, recognized by cell 
surface receptors, to the appropriate intracellular target molecules. MAPK cascades consist of three 
core components: A MAPK, activated by a MAPK kinase (MAPKK), which again is activated by a 
MAPKK kinase (MAPKKK). Four MAPK cascades are known: The ERK1/2, JNK, p38 (described 
below) and ERK5 pathways. MAPKs are involved in regulation of a vast variety of cellular 
processes, ranging from gene expression, mitosis, cell-movement and metabolism to apoptosis. 
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Although individual functions have been assigned to different MAPK cascades, there is substantial 
crosstalk between the different kinases (see Figure 7). For review see (Chang and Karin, 2001; 
Johnson and Lapadat, 2002).
ERK Pathway
ERK1 and ERK2, the two MAPKs in the ERK pathway are widely expressed. They are involved 
in differentiation, mitosis, meiosis and development. The Raf-MEK-ERK pathway is the best 
characterized MAPK signaling pathway. This signaling cascade is activated either through 
stimulation of RTKs or GPCRs by cytokines, growth factors, by virus infection or transforming 
agents. In the case of GPCR, the signal is then transduced via PKC or PKA. Raf (the MAPKKK in 
this cascade), which can be activated by the small G-protein ras, signals to MEK1/2 (MAPKKs), 
which leads to activation of ERK1/2 (MAPK). Activated ERK then translocates to the nucleus, 
where transcription factors are the substrates, leading to expression of genes in response to the 
original stimuli. Among them are Elk1, myc and STAT1/3 (Hilger et al., 2002; Chong et al., 2003).
Recently it was shown by Yang et al. that prostaglandin A2 mediates stabilization of the cyclin-
dependent kinase inhibitor p21 mRNA. Inhibition of the ERK pathway did inhibit this stabilization 
and the formation of a HuR-p21 mRNA complex, implicating a role of the ERK pathway in 
regulation of HuR activity (Yang et al., 2004). In vitro phosphorylation assays have shown that ERK2 
























Figure 7: MAPK-pathways. Some of the most important biological responses of these pathways are mentioned. 
MAPK: Mitogen activated protein kinase, MAPKK: MAPK kinase. MAPKKK: MAPKK kinase.
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stimulated TTP phosphorylation. However, no follow-up publications attributed a functional role to 
this phosphorylation.
JNK (c-jun N-Terminal Kinase) Pathway
The JNK signaling pathway is activated by several different MAPKKKs including members of the 
MEKK group, the ASK1 group, TAKI and MLK3. The signal is transduced via MKK4 and MKK7. 
Activated JNK binds to and phosphorylates the N-terminal activation domain of c-jun. Trans 
activation of c-jun increases expression of genes with AP-1 sites in their promoters e.g. c-jun itself, 
ATF-2, Elk1, p53 and others. JNKs activation is involved in proliferation, differentiation, apoptosis 
and survival signaling.
Activation of stress-induced JNK was shown to stabilize ARE-mRNA (Chen et al., 1998; Ming 
et al., 1998). Interestingly, in mast cells JNK mediates ionomycin-induced stabilization of ARE-
mRNA, but activation of JNK in NIH3T3 cells has no effect on mRNA stability (Ming et al., 2001). 
This indicates that, dependent on the cell type, ARE-mRNA stability is controlled by different 
pathways.
p38 MAPK Pathway
There are four p38 kinase isoforms α, β, γ and δ, with p38α being the best characterized. p38 MAPKs 
are key regulators of infl ammatory cytokines and play an important role in immune response. 
Various stress signals such as UV-irradiation, LPS, inhibition of protein synthesis, osmotic- or heat-
shock activate the p38 MAPK signaling cascade. The signals are transduced via MEK3/6 (MAPKK) 
to p38. Interestingly, p38 has also been found to be activated by TAB1, which is not an MAPKK 
but rather a scaffold protein without known catalytic activity. This indicates that in addition to the 
MAPK signaling modules other regulatory mechanisms exist (reviewed in (Johnson and Lapadat, 
2002)). 
p38 has been reported by several groups to be involved in stability control of ARE-mRNA (Dean 
et al., 1999; Winzen et al., 1999; Brook et al., 2000; Clark et al., 2003; Frevel et al., 2003; Tchen 
et al., 2004; Winzen et al., 2004). HuR has been shown to act in concert with p38 in stabilizing 
IL-3 mRNA (Ming et al., 2001), although direct phosphorylation of HuR was not detected. 
TTP, on the other hand, can be phosphorylated by p38. This phosphorylation inhibits its ARE 
binding activity (Carballo et al., 2001; Zhu et al., 2001). Also MAPK activate protein kinase 2 
(MAPKAPK2 or MK2), a downstream kinase of p38, has been implicated in RNA stabilization 
(Neininger et al., 2002). MK2 is able to phosphorylate TTP in vitro (Mahtani et al., 2001). MK2 
mediated phosphorylation of TTP could be mapped to S54 and S178 and was found to facilitate 
14-3-3 binding. 14-3-3-interaction inhibits TTP activity and leads to exclusion of TTP from stress 
granules (Johnson et al., 2002; Chrestensen et al., 2003; Stoecklin et al., 2004). In contrast to these 
data, phosphorylation of TTP by MK2 has also been shown to be required for effi cient TNFα-ARE 
binding (Mahtani et al., 2001). 
Different MAPK pathways seem to converge on TTP. Cao and coworkers could show that recombinant 
TTP is phosphorylated by p38, ERK2 and JNK, however, none of these phosphorylations did affect 
RNA binding (Cao et al., 2003). Further, Ming et al. (Ming et al., 2001) in our lab showed that TTP 
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antagonizes ARE-mRNA stabilization by p38 and PI3-K, indicating that TTP is not inactivated 
by phosphorylation through these pathways. The data summarized here does still not satisfyingly 
explain the functional role of TTP phosphorylation. Further experiments are needed to dissect the 
effects of all these pathways on AUBPs.
14-3-3 Proteins
The 14-3-3 proteins are involved in a multitude of cellular processes such as cell cycle control, 
stress response and apoptosis. They have been found in all eukaryotic organisms ranging from 
yeast (2 isoforms) to mammals, where seven isoforms have been described (β, γ, ε, σ, ζ, τ and η). 
14-3-3 proteins were the fi rst proteins described to bind specifi cally to phospho-serines in one of 
the following motifs: R-S-X-pS-X-P (mode 1) or R-X-X-X-pS-X-P (mode 2) (Yaffe et al., 1997). In 
the last few years over 200 interacting proteins have been identifi ed (Rubio et al., 2004), refl ecting 
the complexity of 14-3-3 function. Well-characterized examples are Raf-1, BAD, or Cdc25. 14-3-3-
interaction can affect the localization of proteins, their enzymatic activity, DNA-protein or protein-
protein interactions (reviewed in (van Hemert et al., 2001; Tzivion and Avruch, 2002; Mackintosh, 
2004). Many PKB targets bind to 14-3-3 upon phosphorylation, as the PKB consensus sequence (R-
X-R-X-X-S/T-φ) may overlap the optimal 14-3-3 binding sequence (Tzivion and Avruch, 2002).
MK2 induced interaction of TTP with 14-3-3 has already been discussed in the previous chapter. 
14-3-3 also interacts with BRF1, as suggested by results from a yeast two-hybrid screen (Bustin and 
McKay, 1999) and from GST-pulldown experiments (Johnson et al., 2002). Recently, we were able 
to show that phosphorylation of BRF1 by PKB inactivates its decay promoting activity probably by 
binding 14-3-3 (Schmidlin et al., 2004).
Wnt Pathway
The Wnt signaling cascade induces a wide range of responses from cell proliferation to 
differentiation. Extracellular Wnt signals interact with members of the Frizzled family of serpentine 
receptors. These activate the cytoplasmic Dishevelled (Dvl) protein, which inhibits the constitutive 
proteasomal destruction of β-catenin. β-catenin accumulates in the nucleus, where it interacts with 
DNA-bound TCF and LEF family of transcription factors to activate transcription of target genes 
(for review see (Moon et al., 2004)).
Briata et al. showed that activation of the Wnt-β-catenin pathway not only induces transcription of 
Pitx2, a transcription factor regulating genes, such as c-jun, cyclin D1 and D2, but also stabilizes 
the Pitx2, c-jun, cyclin D1 and D2 mRNA. The stabilization is probably achieved by reducing the 
interaction of the ARE of these mRNAs with the destabilizing proteins KSRP and TTP and by 
facilitating the interaction of the RNA with the stabilizing HuR (Briata et al., 2003).
Regulation of mRNA Stability
As summarized above, activation of many signaling pathways leads to stabilization of ARE-
containing mRNA. The different signals seem to converge on the AUBPs. The sum of the incoming 
signals decides over the fate of the mRNA. Due to the multitude of signaling pathways and AUBPs, 
tight regulation of the mRNA turnover can be achieved.
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In addition to the control via AUBPs, mRNA turnover seems to be coupled to translation. Mutations 
in translation initiation factors lead to increased rates of deadenylation and decapping of yeast 
mRNA (Schwartz and Parker, 1999).
Recent unpublished data presented at the annual RNA conference of the RNA society 2004 show 
that stabilization of ARE-mRNA involves reduction of PARN activity via proteasomal degradation. 
This effect seems to be mediated by AUBPs (Biswas et al. abstract 454). Further, BRF1 and TTP 
have been shown to interact with the Dcp1/2p decapping complex and with the hCcr4d-hCaf1z 
deadenylation complex (Lykke-Andersen and Wagner, 2005). In the case of TTP the binding activity 
was mapped to the N-terminal domain. Further, it has been shown that the cap binding protein eIF4G 
interacts with the poly(A) binding protein PABP (Imataka et al., 1998; Tarun and Sachs, 1996). This 
leads to model, where translation and mRNA degradation are tightly coupled. The mRNA forms a 
circular structure with multiple protein complexes interacting with different regions of the mRNA 
(e.g. cap, ARE or poly(A)-tail) and with each other. The composition and the exact structure of these 
complexes, which seems to be regulated by external stimuli, determine the fate of the bound RNA.
The Project(s)
The project(s) aimed at understanding, how signal transduction pathways regulate the activity of 
AUBPs, and subsequently affect mRNA turnover. The main focus of this work was laid on BRF1, 
as very little was known about its regulation. Four different points were addressed during these 
studies: 
Regulation of BRF1 by Phosphorylation at Serine 92. First, the regulation of BRF1 by 
phosphorylation was investigated. In silico analysis of the protein sequence of BRF1 revealed many 
putative phosphorylation sites. Serine 92 (S92), which is placed in the context of a PKB consensus 
site, was already shown by mass spectrometry to be phosphorylated by PKB in vitro (Schmidlin et 
al., 2004). This modifi cation was now investigated in vivo. To achieve this, a phospho-S92-specifi c 
antibody was purifi ed, characterized and used for detection of in vivo phosphorylation. The stability 
of ARE-containing message was investigated under conditions of BRF1 phosphorylation. 
Regulation of BRF1 by Phosphorylation at sites different from S92. Second, the question was 
addressed, whether other kinases than PKB are involved in regulating BRF1 activity, as it is 
suggested by the presence of the additional putative phosphorylation sites. Arsenite- (in NIH3T3 
cells) and insulin-treatment (in HIRc-B rat fi broblasts, overexpressing the human insulin receptor) 
was used to induce hyperphosphorylation of BRF1. This could be visualized by a shift in 
electrophoretic mobility of the protein. In an attempt to identify the pathways involved, different 
inhibitors were tested for their ability to inhibit hyperphosphorylation of BRF1. Comparison of the 
sequences of TTP and BRF1 revealed S203 as the homologous site of S178 in TTP. S178 in TTP is 
known to be phosphorylated by MK2 and facilitate 14-3-3 binding. Therefore, S203 was chosen for 
more detailed analysis. The serine to alanine mutant (S203A) was compared to the wild-type protein 
in respect to electrophoretic mobility and decay promoting activity.
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Localization of AUBPs. In a third part, the subcellular localization of the four AUBPs HuR, AUF1, 
BRF1 and TTP was investigated, as nucleo-cytoplasmic shuttling of these proteins might be part 
of their regulation. The questions were asked, whether changes in stability of ARE-containing 
mRNA involves changes in localization of AUBPs and whether stabilizing and destabilizing 
proteins are differently regulated. By transfection of activated kinases or by drug treatment, 
specifi c pathways could be turned on and their effect on localization of the AUBPs was analyzed by 
immunofl uorescence. 
Involvement of BRF1 in Cell Cycle Control. The last part of the work was aimed at investigating the 
physiological role of BRF1. ARE-mRNA turnover has been shown to play a role in cell cycle control. 
Therefore, the question was addressed, whether BRF1 plays a role in this process. For this purpose, 
a cell line with doxycycline-repressible BRF1 expression was established. Cell cycle progression 
of synchronized cells was analyzed by propidium iodide staining followed by fl ow cytometry and 
by [3H]-thymidine incorporation. Cells with physiological BRF1 levels were compared to cells 
overexpressing BRF1 and to cells with reduced BRF1 expression (RNAi). 
RESULTS
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The results section of this thesis is divided into four parts. First, after a summary of previous data 
from the lab, leading to this work, the in vivo phosphorylation of BRF1 at S92 will be discussed. 
In a second part, additional putative phosphorylation sites in BRF1 will be analyzed. Third, the 
localization of BRF1 and three other AUBPs (TTP, HuR and AUF1) will be investigated and in a 
fourth part the question will be addressed, whether BRF1 plays a role in cell cycle regulation.
BRF1 is Phosphorylated at S92
Previous Work from the Laboratory
Several signal transduction pathways have been found to participate in the regulation of ARE-
mRNA stability. Previous work in our lab started by Ming et al. showed that both the PI3-K and 
the p38 kinase pathway are independently involved in stabilization of ARE-mRNA (Ming et al., 
2001). Subsequent work by Sabrina Leuenberger showed that PKB, a downstream element of 
PI3-K, stabilizes ARE-mRNA, indicating that the stabilizing effect of PI3-K is exerted via this axis. 
As mentioned in the introduction, some AUBPs have been shown to be direct targets of signaling 
pathways. TTP, for instance, is phosphorylated by p38 (Carballo et al., 2001; Zhu et al., 2001), by 
the p38 downstream kinase MK2 (Stoecklin et al., 2004; Chrestensen et al., 2003), by JNK (Cao 
et al., 2003) and by ERK2 (Taylor et al., 1995). Our lab is mainly interested in BRF1, which was 
functionally cloned by Georg Stoecklin and Marco Colombi (Stoecklin et al., 2002). In the case 
of BRF1 no regulatory events have been described, when this study was started. Therefore, the 
question was asked, whether BRF1 activity is regulated via direct phosphorylation, similar to TTP, 
and if so, which signaling pathways are involved in this regulation.
The protein sequences of murine and human BRF1 (SwissProt database; accession number P23950 
and Q07352, respectively) contain consensus motifs for many putative phosphorylation sites (Figure
 8/ http://scansite.mit.edu/ Obenauer et al., 2003). Serines 90 and 92 (S90, S92) are placed in the 
context of two overlapping PKB consensus sites (R-X-R-X-X-S-φ (Obata et al., 2000)). In the lab of 
Brian Hemmings at the Friedrich Miescher Institute in Basel it could be shown by mass-spectrometry 
of in vitro phosphorylated BRF1 that S92 is effi ciently phosphorylated by PKB (Schmidlin et al., 
2004). To further study the function and the regulation of BRF1, recombinant BRF1 (rBRF1) was 
tested in an in vitro decay system. This approach has successfully been used by others (Ford et
al., 1999; Chen et al., 2000; Gao et al., 2001) to decipher different aspects of post-transcriptional 
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regulation of mRNA. Indeed, addition of rBRF1 to slowC cell extracts, lacking BRF1 expression, 
due to frameshift mutagenesis (Stoecklin et al., 2002), did promote degradation of ARE-containing 
RNA. Interestingly, phosphorylation of BRF1 at S92 inhibited its decay promoting activity in the 
same assay. A mutant version of BRF1, with S90 and S92 replaced by alanine (BRF1S90/92A) was 
refractory to this inhibition, indicating that S92 is important for PKB mediated inactivation of BRF1. 
(As residual phosphorylation of the S92A mutant was observed in in vitro kinase assays, the double 
mutant S90/92A was routinely used, to circumvent unspecifi c phosphorylation of S90). Looking 
for a possible mechanism to explain the inhibition of BRF1 by phosphorylation, the attention was 
turned to the 14-3-3 protein, which is known to be involved in many signaling events.
14-3-3 interacts with more than 250 different proteins, mostly in a phosphorylation dependent manner 
(Meek et al., 2004; Rubio et al., 2004). Among them we fi nd many PKB targets. One hypothesis, 
therefore, was that 14-3-3 binds to phosphorylated BRF1 and, thereby, inhibits its activity. Indeed, it 
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Figure 8: Putative phosphorylation sites in human (huBRF1) and murine BRF1 (muBRF1) are shown in red (sequences 




could be shown that rBRF1 can pull down 14-3-3 from cellular extracts only when pre-treated with 
activated PKB. Further, 14-3-3 co-purifi es with His-tagged BRF1, but not with BRF1S90/92A from 
Cos7 cells upon activation of the PKB signaling pathway (Schmidlin et al., 2004).
Purifi cation and Characterization of a phospho-S92-BRF1 Antibody 
So far, the fi ndings were based on in vitro experiments. However, it is well known that phosphorylation 
observed in vitro may not refl ect the physiological situation. To investigate, whether S92 is a 
regulatory site in vivo, an antibody directed to a trisdekapeptide containing phosphorylated S92 
of BRF1 (F-R-D-R-S-F-pS-E-G-G-E-R-L) was raised in rabbits (immunization of the rabbit was 
performed by Brigitte Gross). I then tested the sera of three rabbits for their ability to detect rBRF1, 
pre-incubated with active PKB, on Western blot. One serum (#6) tested positive and was specifi c 
for phosphorylated BRF1, as untreated rBRF1 did not give rise to a Western signal (Figure 9A, 
compare lanes 10 and 11). For purifi cation, 
serum #6 was run over an affi nity Sepharose
4B column (Pharmacia Biotech) with the 
phospho-peptide, used for immunization, 
coupled to the beads. After washing, the 
antibody was eluted from the column at 
pH 2,6. The eluate was fractionated in 
1ml aliquots and neutralized to pH 7. The 
fractions were tested again on Western 
blot for their ability to distinguish between 
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Figure 9: A: rBRF1 was incubated alone or with 
activated PKB. Pre-immun serum  (PI) and the 3 
different sera (1/10 diluted) from the immunized rabbits 
(#4, #5, #6) were tested on Western blot for their specifi c 
recognition of phosphorylated BRF1. 10ng of BRF1 
protein were loaded. B: Affi nity purifi ed fractions 3 
to 6 from serum #6 (1/200 diluted), were tested as in 
A. As a loading control the same blot was probed with 
a rabbit anti-BRF1 antibody (Raineri et al., 2004). 
C: rBRF1 was pre-incubated with activated PKB 
and indicated amounts were processed for Western 
blot. Phosphorylated rBRF1 was detected with serum 
#6, fraction 4 (1/200). D: Where indicated (+pBRF1 
pept.), the antibodies recognizing BRF1 and phospho-
S92-BRF1 were pre-incubated with 50µg of the 
phospho-peptide used for immunization (F-R-D-R-S-
F-pS-E-G-G-E-R-L) before immunodetection. As an 
additional control PKB levels were detected. 
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rBRF1 (Figure 9B). Fraction 4 gave a strong signal in the case of phosphorylated rBRF1 and did not 
detect unphosphorylated rBRF1 (compare lanes 5 and 6). This fraction was further characterized. 
Titration of rBRF1 revealed that approximately 1ng of phosphorylated rBRF1 could still be detected 
(Figure 9C, lane 5) and that the specifi city for phosphorylated rBRF1 was about 10-fold higher than 
for unphosphorylated rBRF1, because 10ng unphosphorylated rBRF1 gave raise to a comparable 
signal to 1ng of phosphorylated rBRF1 (Figure 9C, compare lanes 2 and 5). As an additional control 
for its specifi city, the antibody was pre-incubated with the phospho-peptide used for immunization 
before immunodetection. The phospho-signal could be competed away (Figure 9D, compare lanes 3 
and 6), whereas pre-incubation of the antibody, recognizing the C-terminus of BRF1 (Raineri et al., 
2004), with the same peptide had no effect (middle panel, compare lanes 2, 3 with 5, 6).
Phosphorylation of S92 by Transfected PKB
Having characterized the phospho-S92-BRF1 antibody, the question was addressed, whether 
BRF1 is phosphorylated at S92 in vivo and whether PKB is, indeed, the kinase responsible for this 
modifi cation. For this purpose wild-type BRF1 (BRF1wt) and BRF1S90/92A (again the double 
mutant was used to avoid residual phosphorylation of S90) were transfected together with activated 
m/pPKB (Andjelkovic et al., 1997) or kinase dead PKB (kdPKB) into NIH3T3 cells. m/pPKB is a 
myristoylated/palmitylated form of PKB that is permanently localized to the plasma membrane and 
therefore constitutively activated (see Introduction, Figure 6). 24h after transfection, the samples 
were processed for Western blotting and phospho-S92-BRF1 (pBRF1), phospho-S473-PKB (pPKB, 
activated PKB) and α-tubulin (α-tub), as a loading control, were visualized by the appropriate 
antibodies. As seen in Figure 10A, transfection of BRF1wt together with kdPKB gave rise to a weak 
signal, detected with the phospho-S92-BRF1 antibody. This band was absent, if BRF1S90/92A was 
transfected (Compare lanes 1 and 2), indicating that the signal is indeed specifi c for phosphorylated 
S92. The phospho-S92-BRF1 antibody detects also an unspecifi c band, migrating slightly above 
BRF1. The specifi c size for BRF1 is indicated by the arrow. Cotransfection of highly active m/pPKB 
(see middle panel, lanes 3 and 4) did strongly increase the phosphorylation of S92, with no effect 
on BRF1S90/92A (lanes 3, 4). This experiment shows that PKB does indeed phosphorylate BRF1 
at S92 in vivo. However, these data do not clarify, whether the weak phosphorylation detected in 
lane 1 is due to background activity of endogenous PKB (which is very weak, as seen in the middle 
panel) or another kinase. 
The same experiment was also performed in HIRc-B cells (kindly provided by P. Blackshear 
(McClain et al., 1987)). These rat fi broblast cells overexpress the human insulin receptor, rendering 
them hypersensitive to insulin stimulation. HIRc-B cells were chosen in prospect of future 
experiments, using insulin for PKB activation. In addition to the experiment described in Figure 
10A, BRF1wt and BRF1S90/92A were also transfected alone and PKB activity was inhibited with 
wortmannin (WM, a PI3-K inhibitor) to test, whether background PKB activity can account for the 
phosphorylation of exogenous BRF1. The levels of phospho-S92-BRF1 (pBRF1), BRF1, active 
PKB (pPKB), total PKB and α-tubulin (α-tub), as a loading control, were visualized. The BRF1 
antibody recognizes in addition to BRF1 also BRF2, which shares the C-terminal peptide used 
for immunization. The two proteins can be separated by size. RNAi experiments had previously 
revealed that the upper band, indeed, corresponds to BRF2 (Brigitte Gross, unpublished data). 
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Interestingly, the results clearly showed that the phosphorylation of BRF1 at S92 under these 
conditions is WM-insensitive, as treatment with WM, which completely blocked PKB activation 
(middle panel, compare lane 1 and 2) did not reduce the phosphorylation of BRF1 at S92 (Figure 
10B, compare lane 1 and 2, upper panel). To assure that the signal detected by the phospho-S92-
BRF1 antibody is indeed phospho-specifi c, BRF1S90/92A was analyzed. As expected, the phospho-
BRF1 signal was strongly reduced in this case (lanes 3 and 4, upper panel). Again the topmost band 
in the upper panel is unspecifi c. Transfection of m/pPKB alone did lead to high levels of activated 
PKB (lane 5, middle panel) and phosphorylated endogenous BRF1 could be detected (upper panel), 
despite the low levels of BRF1 (second panel from top). Transfection of kinase dead PKB (kdPKB) 
had no effect on BRF1 phosphorylation (lane 6, upper panel).
Cotransfection of BRF1wt or BRF1S90/92A together with m/pPKB or kdPKB resulted in a similar 
pattern to the one seen in NIH3T3 cells. Again a background phosphorylation of BRF1 could 
be detected, if kdPKB was cotransfected with BRF1wt (Figure 10B, lane 7), which increased 
substantially, if the activated form of PKB was transfected (compare lanes 7 and 9). Phosphorylation 
was specifi c to S92, as no phosphorylation of the BRF1S90/92A mutant could be detected under 
either condition. These data confi rm the fi nding that BRF1 is phosphorylated in vivo by PKB at S92 





































Figure 10: A: NIH3T3 (B2A2 clone23 (Xu et al., 1998)) were transfected with bsd-HisBRF1wt (wt), bsd-HisBRF1S90/
92A (AA), activated PKB (m/p) or PKB kinase dead (kd), as indicated. 24h after transfection, cellular extracts were 
processed for Western blotting and phosphorylated BRF1 at S92 (pBRF1), activated PKB (pPKB) and α-tubulin were 
detected. B: HIRc-B cells were transfected with bsd-HisBRF1wt (wt), bsd-HisBRF1S90/92A (AA), activated PKB (m/
p) or PKB kinase dead (kd) alone or in combination. After WM addition (200nM, 45min), where indicated, extracts were 
processed for Western blotting and phospho-S92-BRF1 at S92 (pBRF1), total BRF1, BRF2, activated PKB (pPKB), total 
PKB, and α-tubulin were detected.
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Phosphorylation of S92 in BRF1 by Insulin
While the data above established that PKB is able to phosphorylate S92, it has to be considered that 
the levels of activated PKB following transfection are unphysiologically high. To further investigate 
the signifi cance of S92 phosphorylation under more physiological conditions, NIH3T3 cells were 
treated with insulin, a known activator of PKB (Burgering and Coffer, 1995). PKB background 
activity was reduced, by starving the cells overnight in serum-free medium. The phosphorylation 
status of BRF1 was analyzed by Western blot together with total BRF1 levels and levels of activated 
PKB (pPKB). As a control, m/pPKB transfected extract was run on the same gel. As expected, 
m/pPKB strongly activated PKB (Figure 11A, lane 4, lower panel). Under the same conditions BRF1 
phosphorylation was induced (lane 4, upper panel) with no change in BRF1 protein levels (lane 4, 
middle panel). Also after insulin-treatment for 
15 minutes a weak phospho-S92-BRF1 band 
was seen (upper panel, middle band), however, 
PKB activation was only minimal as revealed 
by detection of phospho-S473-PKB (Figure 11A, 
lane 2, lower panel). Nevertheless, PKB seemed to 
be the kinase responsible for this phosphorylation, 
as the phospho-S92-BRF1 signal disappeared, 
if the cells were pre-treated with the PI3-K 
inhibitor wortmannin (WM) for another 30’ prior 
to insulin addition (compare lanes 2 and 3, upper 
panel). 
To verify these fi ndings and to increase the 
insulin induced PKB activation, further insulin 
stimulation experiments were performed in 
HIRc-B rat fi broblasts, which highly express 
the human insulin receptor and are widely used 
to investigate insulin signaling (McClain et al., 
1987). In these cells, insulin strongly activated 
PKB (Figure 11B, lane 2, middle panel). 
Phosphorylation of BRF1 at S92 could be detected 
under conditions of PKB activation. In contrast to 
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Figure 11: A: NIH3T3 cells were starved overnight and 
stimulated with insulin (20µg/ml, 15min) after pretreatment 
of WM (200nM, 30min) as indicated. As a control NIH3T3 
cells transfected with m/pPKB were analyzed on the same 
blot. BRF1 phosphorylated at S92 (pBRF1), total BRF1 and 
activated PKB (pPKB) levels were analyzed. B: HIRc-B 
cells were treated as described in A. In addition α-tubulin 
was detected as a loading control. C: MEF-PKBα +/+ and 
-/- cells were treated as described in A. pBRF1, pPKB, total 
PKB and α-tubulin levels were analyzed
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was not completely abolished by pre-treating the cells with WM, which completely blocked PKB 
activation (compare lanes 2 and 3). Again, this result indicates that, in addition to PKB, another 
kinase is able to phosphorylate S92. To further strengthen the point that PKB phosphorylates BRF1 
at S92 in vivo, the effect of insulin stimulation was tested in mouse embryonic fi broblasts lacking 
PKBα (MEF-PKBα -/- (Yang et al., 2003) kindly provided by Brian Hemmings). Again, these 
cells and the corresponding wild-type control cells were starved overnight and then treated for 30 
minutes with WM, before insulin was added for 15 minutes. As expected, the MEF-PKBα -/- cells 
showed reduced levels of PKB (Figure 11C, third panel, lanes 4-6). The antibody used for PKB 
detection cross reacts with all three PKB isoforms. The residual signal, therefore, arises form the 
β and γ isoform still present in the knockout cells. Similar to the wild-type cell also the knockout 
showed activated PKB after insulin stimulation, which was inhibited by WM, again arising from 
the other two isoforms. In the wild-type cells, a basal BRF1 phosphorylation could be detected 
(lane 1, upper panel), which was increased upon insulin stimulation (lane 2) and again reduced 
by WM (lane 3). Interestingly, BRF1 phosphorylation was absent in the MEF-PKBα -/- cells and 
only marginally induced upon insulin stimulation (compare lanes 4 and 5). These data indicate that 
PKBα is responsible for insulin induced BRF1 phosphorylation in MEFs.
ARE-mRNA is Stabilized under Conditions of BRF1 Phosphorylation
To test the effect of BRF1 phosphorylation and to check, whether in vivo PKB mediated BRF1 
phosphorylation inhibits the decay promoting activity of BRF1 similar to the in vitro situation, 
the stability of ARE-mRNA was investigated upon stimulation of HIRc-B cells by a physiological 
stimulus, such as insulin. For this purpose, a doxycycline controllable reporter system was chosen: 
The tetracycline-controlled transactivator (tTA), a fusion protein of the tetracycline (tet) repressor 
(tetR) and the c-terminal activation domain of the VP16 protein of herpes simplex virus, can bind 
to the tet operator sequence (tetO) present in the tet responsive element (TRE). If the TRE is placed 
next to a transcriptionally silent minimal CMV promoter lacking the enhancer (P
minCMV
), binding 
of tTA leads to transactivation. In the presence of doxycycline (dox) or tet tTA-TRE interaction is 
inhibited and transcription is silenced (Figure 12).
HIRc-B cell were cotransfected with the tTA transactivator and a dox-controllable β-globin reporter 
construct with the 3’UTR of IL-3, containing a strong class II ARE. The cells were transfected 
in a 15cm dish and splitted into three 10cm dishes 24h after transfection. After another 24hrs, 
the cells were treated for 30min with WM, followed by 15min insulin, where indicated, and then 
transcription was stopped by addition of dox. RNA levels of the β-globin-IL3-UTR construct were 
analyzed by northern blot. In unstimulated cells the reporter message was degraded with a half-life 
of approximately 2h (Figure 13A, lanes 1-3 and quantifi cation). Insulin stimulation did stabilize the 
message signifi cantly (lanes 4-6) and WM pre-treatment reversed this stabilizing effect (lanes 7-9). 
To underline the importance of the regulation of BRF1 by PKB, I sought to fi nd an endogenous 
target mRNA, which is regulated similar to the reporter construct. The attention was turned to 
vascular endothelial growth factor (VEGF). In a chip experiment comparing transcript levels of 
slowC cells (frameshift mutant, lacking BRF1 expression) and slowC revertant cell lines (Stoecklin 
et al., 2000), elevated levels of VEGF message were found in the slowC cells (I. Raineri and C. 
Moroni, in collaboration with U. Certa et al. Roche, Basel, unpublished data). This data indicate 
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that VEGF message is regulated by BRF1. VEGF is a key regulator of physiological angiogenesis 
during embryogenesis and skeletal growth. It has been found to induce lymph angiogenesis and also 
seems to be important in pathological angiogenesis. VEGF is a survival factor for endothelial cells 
and prevents serum starvation induced apoptosis, probably via the PI3-K-PKB pathway. Expression 
of this factor is induced by hypoxia and several growth factors (e.g. TGFα, β, FGF, PDGF) (see 
(Ferrara et al., 2003) for review on VEGF). Rat VEGF contains 6 AUUUA pentamers and one 
nonamer in its 3’UTR. To investigate the stability of this message, HIRc-B cells were left untreated, 
were treated with insulin alone or pretreated with WM. ActD-chase experiments were performed 
and the mRNA levels were monitored by northern blotting. VEGF message was expressed at very 
low levels and disappeared quickly after ActD-treatment (Figure 13B lanes 1-4). Treatment with 
insulin did stabilize the VEGF mRNA slightly (lanes 5-8). Inhibition of PKB by WM did abolish 
this effect (lanes 9-12). In both experiments (Figure 13A and B), the message was only stabilized in 
the fi rst hour after insulin-treatment. This correlates with the fact that PKB activation peaks after 15 
minutes of insulin-treatment and decreases after 30 minutes as shown in the Western blot in Figure 
13C, where phospho-S473-PKB levels were analyzed under the same conditions. During the writing 
of this work, it has been reported by Ciais et al. that BRF1 interacts with the ARE of VEGF and 
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Figure 12: Tet-Off System. If doxycycline 
(dox) is present at high concentrations, it 
binds to the tTA protein, expressed from 
the pTet-Off vector. In the dox bound form, 
tTA is not able to bind to the tet responsive 
element (TRE) and no transactivation takes 
place. If no dox is bound to tTA, interaction 
with the TRE takes place and the gene of 
interest is transcribed due to transactivation.
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The ARE-Dependent mRNA-Destabilizing Activity of BRF1 is Regulated by PKB
The work presented so far was published in December 2004 in the Journal of the European Molecular 
Biology Organization (EMBO). The paper is shown on the following pages.
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Figure 13 A: Dox-repressible β-globin-IL3-3’UTR reporter (pSRL) was cotransfected with the tTA transactivator 
(pTet-Off) into HIRc-B cells. 24h after transfection, cells were split into 3 dishes. 24h late, cells were treated with 
WM (200nM) for 30min and/or insulin (20µg/ml) for 15 additional minutes as indicated. Then, cytoplasmic RNA was 
extracted and reporter mRNA levels were analyzed by northern blotting. The graph shows the mean values of three 
independent experiments normalized to 18S rRNA with standard deviation. B: ActD-chase experiment of endogenous 
VEGF message in HIRc-B cells. Cells were pretreated for 30min with WM (200nM) and 15 additional minutes with 
insulin (20µg/ml) as indicated. One representative blot is shown out of three independent experiments. C: Time course 
of PKB activation in HIRc-B cells upon insulin stimulation (20µg/ml), analyzed by Western blot for PKB activation 
(pPKB) and total PKB levels.
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WM-Insensitive Kinase Phosphorylates BRF1 at S92
As seen in Figures 10B and 11B, in addition to PKB, a WM-insensitive kinase phosphorylates BRF1 
at S92 in insulin stimulated HIRc-B cells. To further analyze the nature of this WM-insensitive 
phosphorylation, cells were starved overnight, pretreated with inhibitors for MEK1/2 (UO126), 
p38 MAPK (PD169316) and PI3-K (WM) for 1h, prior to stimulation with insulin. Then, cellular 
extracts were processed for Western blotting. As a control for the effect of the inhibitors, activated 
PKB (pPKB, control for WM), activated p38 (pp38, control for PD169316) and activated ERK1/2 
(pERK1/2, control for UO126) were detected with the respective antibodies. In the HIRc-B cells, 
insulin did activate all three tested kinases (Figure 14A, lane 2, panels pPKB, pp38, pERK1/2). 
Looking at the phosph-S92-BRF1 (topmost panel), again three bands were detected, the highest 
being unspecifi c and serving as loading control and the middle one being the band of interest. This 
middle band is absent in starved cells (lane 1) and induced by insulin (lane 2). In this experiment, 
WM could only marginally inhibit this phosphorylation (lane 3). Also the p38 inhibitor PD169316 
could not reduce the S92 phosphorylation (lane 4; total protein levels are slightly reduced in this 
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Figure 14: A: HIRc-B cells were starved overnight, pre-treated with inhibitors for PI3-K (WM), p38 (PD169316) or 
MEK1/2 (UO126) before insulin stimulation (15min, 20µg/ml). Protein extracts were processed for Western blot and 
BRF1 phosphorylated at S92 (pBRF1), total BRF1, BRF2, activated PKB (pPKB), total PKB, activated p38 (pp38), 
total p38 activated ERK1/2 (pERK1/2) and tubulin. B: Western blot of endogenous BRF1 and BRF2 from starved or 
insulin (15min, 20µg/ml) treated HIRc-B cells. The cells were lysed in absence of phosphatase inhibitors and incubated 
for 30min with λ-PPase where indicated.
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and 9, upper panel). Combination of all three inhibitors completely abolished detectable BRF1 S92 
phosphorylation (lane 9). These data argue that S92 phosphorylation upon insulin in HIRc-B cells 
is not only mediated by PKB, but most likely also by ERK1 or 2, the two downstream kinases of 
MEK1/2.
BRF1 is Phosphorylated at Additional Sites to S92
Apart from the two PKB consensus sites, many additional putative phosphorylation motifs can 
be found in the sequences shown in Figure 8. Serine 54 (S54) is a putative PKA site (R-(X)-X-S). 
According to Stokoe et al. (Stokoe et al., 1993), S54 matches also to the MK2 consensus (φ−X-R-
X-X-S). As discussed previously, S90 and 92 are placed in the context of two overlapping PKB 
consensus sites (R-X-R-X-X-S-φ) (Obata et al., 2000), which closely resemble the PKA consensus 
(Obenauer et al., 2003). S203 is the homologous site to S178 in TTP, which is phosphorylated by 
MK2 (Chrestensen et al., 2003; Stoecklin et al., 2004) and is also a putative PKC site (Obenauer 
et al., 2003). Further, we fi nd an ERK1 site at threonine 227 (T227) (P-(X)-X-S/T-P) (Davis, 
1993), an MK2  site (S283) and a GSK3 site (S294) (Davis, 1993; Pearson and Kemp, 1991). The 
phosphorylation consensus sequences for these different kinases are very similar and they vary 
slightly between different references. Therefore, this sequence searches may only serve as a lead for 
further investigations. 
Apart from the sequence analysis, there is also experimental evidence for additional phosphorylation 
sites to S92: BRF1 (endogenous and exogenous) can be detected as multiple, differently migrating 
bands by Western blot. In addition, and in contrast to the in vitro decay data (Schmidlin et al., 2004), 
activated PKB is not able to fully inactivate the decay promoting activity of cotransfected BRF1 in 
ActD-chase experiments. Activated rasV12, however, is completely dominant over the destabilizing 
activity of cotransfected BRF1wt and BRF1S90/92A (Sabrina Leuenberger, PhD thesis, 2004 and 
unpublished data by Min Lu). This argues that in addition to the PKB pathway, targeting S92, also 
other pathways, phosphorylating different sites, are important for BRF1 regulation  
Insulin-Induced Phosphorylation
Analyzing endogenous BRF1 in the experiment shown in Figure 14A (second panel from top), an 
interesting pattern can be observed. In HIRc-B cells, the multiple BRF1 bands, observed under 
unstimulated conditions (lane 1), condense to one slowly migrating, probably hyperphosphorylated 
form after insulin-treatment (lane 2). This insulin-induced upshift is WM (lane 3) and PD169316 
(lane 4) insensitive. Pre-treatment of HIRc-B cells with the MEK1/2 inhibitor UO126, on the 
other hand, did reverse this insulin effect (compare lane 2 with lanes 5, 7, 8 and 9). The insulin-
induced upshift was only observed in the HIRc-B but not in NIH3T3 cells (Figure 11A, lane 2). 
Overexpression of the human insulin receptor in HIRc-B cells renders this cell line hyper sensitive to 
insulin, activating also signaling pathways different from the PKB-pathway. Activation of ERK1/2
(pERK1/2) and p38 MAPK (pp38) upon insulin-stimulation is shown in lane 2. As the BRF1 
antibody also recognizes BRF2, the phosphorylation pattern of BRF2 could also be investigated. 
Interestingly, BRF2 behaved completely the same way, as BRF1 (compare second and third panel 
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from top). In the presence of the UO126, the BRF2 pattern resembles the one from unstimulated 
cells, whereas the other inhibitors had no effect on the insulin-induced hyperphosphorylation. To 
check, whether the observed upshift of BRF1 and BRF2 is, indeed, due to phosphorylation, cells 
were lysed in buffer lacking phosphatase inhibitors and the extract was treated with Lambda-
Proteinphosphatase (λ-PPase) at 30°C for 30 minutes. As shown in Figure 14B, phosphatase-
treatment did not only reduce the insulin-induced upshift of the two proteins (lanes 3 and 4), but 
also condensed the multiple bands in unstimulated extracts to a faster migrating form. Therefore, the 
different forms of BRF1 arise from phosphorylation.
Taken together, Figure 14 shows that BRF1 is phosphorylated in response to insulin at S92. 
In addition, an insulin-induced shift can be observed on Western blot. The phosphorylation(s) 
responsible for this upshift seem to be mediated by the ERK1/2 pathway, as the MEK1/2 inhibitor 
UO126 inhibits this phosphorylation. The fact thet transfected BRF1S90/92A runs similar to the 
wild-type protein (Figure 10B) indicates that the site responsible for the different BRF1 forms is not 
S92.
Arsenite-Induced Phosphorylation
Arsenic compounds produce a variety of stress responses in mammalian cells. Arsenite (arsenic 
trioxide) stress, at the molecular level, shares many features with the heat shock response. Similar 
to heat stress, arsenite induces heat shock proteins (HSPs) of various sizes and activates ERK, JNK 
and p38. Through the JNK and p38 pathways, arsenite activates the immediate early genes c-fos
and c-jun. Like other oxygen radical-producing drugs, arsenite induces nitric oxide production, 
nicotinamide adenine dinucleotide (NAD) depletion, DNA strand breaks, and formation of 
micronuclei. (Bernstam and Nriagu, 2000; Liu et al., 1996) Further, arsenite has been found to 
induce stress granules, subcellular compartments, where translationally silent mRNAs are stored 
(Kedersha and Anderson, 2002). 
As arsenite-treatment activates many different pathways, this drug might induce BRF1 
phosphorylation and if so, provide a tool to investigate the pathways involved. To test this, NIH3T3 
cells were transfected with myc-BRF1wt and were treated with arsenite (1mM for 1h). As seen in 
Figure 15A, two major bands of BRF1 were detected in untreated cells (Figure 15A, lanes 1 and 
3, upper panel). After treatment with arsenite, the multiple bands of BRF1 were condensed into 
one high migrating form. (Figure 15A, compare lanes 1 and 2). This effect was WM-insensitive 
(lanes 3 and 4), indicating that the PI3-K-PKB axis plays no role. If so, phosphorylation of S92 
should not be involved in this upshift. To verify this, the infl uence of arsenite on the BRF1S90/92A 
mutant was investigated. Indeed, multiple bands were detected for myc-BRF1S90/92A in untreated 
cells (Figure 15A, lane 5) and arsenite-treatment did alter the migration of mutant BRF1 similar to 
the wild-type (Figure 15A, lane 6). This effect was again WM-insensitive (lanes 7, 8). These data 
show that arsenite-treatment induces modifi cation of BRF1, most likely phosphorylation, which 
does not involve S90/S92 and which is not mediated by the PI3-K-PKB pathway. It still remained 
to be  confi rmed that the observed change in migration is due to phosphorylation. To address this 
question, cell lysates were again treated with λ-PPase. Extracts from untreated cells (Figure 15B, 
lane 2) or from arsenite-treated cells (lanes 3-5) were incubated with 100units of λ-PPase for the 








0 15 30 0 15 30 30





























100 20 4 0
0 60 0 60 0 60 0 60
arsenite (mM) 0 0.05 0.2 1
end BRF1
end BRF2
1 2 3 4 5 6 7 8
1 2 3 4 5
1 2 3 4 5 6 7
1 2 3 4






Figure 15: A: pTRE-BRF1 (BRF1wt) and pTRE-BRF1S90/92A (BRF1AA) were transfected into NIH3T3 cells (B2A2 
clone). 24h after transfection, cells were stimulated with arsenite alone (1mM/ 1h) or pretreated with WM (200nM) for 
30min as indicated. Immunoblotting against the myc-tag was performed. B: Cell extracts of pTRE-BRF1 transfected 
NIH3T3 cells (B2A2 clone) were treated for different time periods (lanes 1-5) or with different amounts of Lambda-
Proteinphosphatase (λ-PPase) (lanes 6-13) as indicated before processing for Western blot. (The asterisk denotes the 
band arising from the λ-PPase) C: TAP-tagged BRF1 was expressed in HT1080 cells. Its electrophoretic mobility was 
investigated in response to arsenite (1mM/ 1h). Extracts were treated for indicated time periods with λ-PPase (20units). 
D: Endogenous BRF1 and BRF2 in NIH3T3 cells were analyzed by Western blot. Cells were stimulated with arsenite 
for 1h, as indicated.
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The Western signal was visualized using CDP-star (Roche), which is activated by phosphatases. 
Therefore, a background signal, arising from the λ-PPase, was detected (denoted with an asterisk). 
Again, arsenite-treatment before lysis induced an upshift of BRF1 (compare lanes 2 and 3). The 
slow migrating form of BRF1 shifted to a single fast migrating form already after 15 minutes of 
phosphatase-treatment (lanes 3-5). This backshift was dependent on the λ-PPase. Lanes 6 to 13 of 
Figure 15B show myc-BRF1 in unstimulated NIH3T3. The extracts were treated with decreasing 
amounts of λ-PPase as indicated. Reduction of the amount of λ-PPase reduced the backshift 
observed (lanes 6 to 11). Incubation of the extracts at 30°C in absence of λ-PPase did not alter the 
migration of BRF1 after 60 minutes (lanes 12 and 13).
To assure that BRF1 and not the myc-tag is phosphorylated, the same set of experiments were 
performed using tandem-affi nity-purifi cation (TAP)-tagged (provided by Don Benjamin; Figure 
15C) and endogenous BRF1 (Figure 15D). The TAP-BRF1 fusion protein was expressed in HT1080 
cells and showed a different pattern from the myc-tagged version, which arose from the different 
sizes of these two proteins (the TAP-tag adds approximately 20 kDa to the protein size). Only one 
major band was detected. However, arsenite induced an upshift of this band (Figure 15C, compare 
lane 1 with lanes  4 and 7). λ-PPase-treatment markedly increased the electrophoretic mobility of 
TAP-BRF1 in both untreated (lanes 1-3) and arsenite-treated cells (lanes 4-6). 
Endogenous BRF1 (Figure 15D) was also analyzed. Treatment of NIH3T3 cells with increasing 
amounts of arsenite induces an upshift of BRF1 (lanes 1 to 4, with the upper arrow showing the 
hyperphosphorylated form).
Taken together, it can be stated that BRF1 exists as differentially phosphorylated forms in 
exponentially growing NIH3T3 cells. Upon arsenite stimulation BRF1 becomes hyperphosphorylated 
in a WM-insensitive manner.
To address the question, which pathways are involved in the arsenite-response, NIH3T3 cells 
were pretreated for 1h with inhibitors for MEK1/2 (UO126 and PD98059), p38 (SB202190 and 
PD169316) and PKB (SH-5) before activation with arsenite or TPA, a strong activator of PKC. 
Only one inhibitor is shown per kinase, as the corresponding inhibitors had an identical effect. As 
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Figure 16: NIH3T3 cells were pretreated for 1h with inhibitors for MEK1/2 (PD98059, 25µM) or p38 (SB202190, 
2,5µM) before stimulation with arsenite (1mM) or TPA (200nM) for another hour. The electrophoretic mobility of 




been discussed above, that PKB mediated BRF1 phosphorylation is not visible as a shift on a 
SDS-PAGE (Figures 10B and 15A). The MEK and the p38 inhibitors alone slightly reduced the 
high migrating form of endogenous BRF1 in the unstimulated extracts (Figure 16, compare lane 
1 with lanes 4 and 7); however, the arsenite-induced hyperphosphorylation could not be inhibited 
(compare lane 2 with lanes 5, 8). TPA-treatment did not alter the pattern of BRF1 (lane 3), but, in 
contrast to unstimulated extracts (lanes 1, 4, 7), the presence of the inhibitors did not reduce the 
high migrating form of BRF1 in TPA-treated cells (lanes 6, 9). Interestingly, combination of the 
MEK and the p38 inhibitor did result in a more prominent effect: In unstimulated extracts only the 
fast migrating (unphosphorylated) form of BRF1 was detected (lane 10), whereas in arsenite-treated 
cells, in addition to the hyperphosphorylated form, a faster migrating band appeared (lane 11). Only 
the TPA-treated extracts did not respond to the inhibition. The fact that phosphorylation of BRF1 
was reduced in unstimulated cells by the combination of the two inhibitors, but not, if the cells were 
treated with TPA, indicates that TPA also can induce BRF1 phosphorylation. Together these data 
suggest that arsenite-treatment leads to phosphorylation of BRF1 by different kinases, probably 
from the p38 and the ERK pathway, as only combination of both inhibitors was able to reduce the 
arsenite-induced hyperphosphorylation. It is also possible that the two kinases target the same site. 
In addition, probably also PKC, which is strongly activated by TPA and not responding to the MEK 
and p38 inhibitors, phosphorylates BRF1. 
Lipopolysaccharide (LPS)-Treatment does not Affect the Motility of BRF1
LPS is a major component of the outer membrane of Gram-negative bacteria, and a very potent 
activator of microbial infl ammation. LPS activates monocytes and macrophages to produce pro-
infl ammatory cytokines, such as TNFα, IL-1, IL-6, IL-8 and IL-12. LPS-induced macrophage 
activation involves various kinase pathways including PKA, PKC, Src–related kinases and the 
MAPK ERK1/2, p38 and JNK (see (Fujihara et al., 2003) and references therein). Treatment of 
RAW 264.7 macrophages has been reported to induce TTP expression and binding of TTP to TNFα
mRNA, dependent on the p38 MAPK pathway (Mahtani et al., 2001). In the same report multiple 
TTP phosphorylation has been reported in response to LPS. Therefore, the question was asked, 
whether LPS also induces BRF1 phosphorylation. RAW 264.7 macrophages were stimulated by 
LPS and cells were lysed at different 
time points. Western blotting 
showed that BRF1 is not expressed 
at detectable levels in unstimulated 
macrophages (Figure 17, lane 1, 5). 
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Figure 17: Raw 264.7 macrophages were 
pretreated with WM (200nM/ 1h) before LPS 
stimulation (5µg/ml) as indicated. BRF2, 




was induced (lanes 3, 4, 7 and 8), but did not show the hyperphosphorylated pattern observed 
in the case of arsenite-treated 3T3 cells or insulin-treated HIRc-B cells (Figure 15/ Figure 17, 
lane 9). Interestingly, BRF2 expression was constantly high and, in addition, already after 15min 
BRF2 shifted to a higher migrating form on the SDS-PAGE. This upshift was WM-insensitive. 
Phosphorylation of BRF1 and BRF2 was very similar in the case of arsenite or insulin-treatment, 
but the behavior of these two proteins differs in response to LPS-treatment. Dependent on the cell-
type and the stimulus the two proteins seem to be affected by the same or by different kinases. In 
addition, it can be seen in Figure 17 that PKB is not activated by LPS (see middle panel), indicating 
that the upshift of BRF2 is not dependent on this kinase.
Phosphorylation of BRF1 by Transfection of Activated Kinases
To further narrow down the kinases involved in BRF1 phosphorylation, cotransfection experiments 
were performed, where activated kinases (m/pPKB, rCD2-p110, MEK6DD, MK2EE, RafCT) and 
activated rasV12 were transfected together with myc-tagged BRF1wt and the mobility of BRF1 
was compared by Western blotting. Activated MEK6 (only slightly), Raf (RafCT) and ras (rasV12) 
were able to upshift BRF1 (Figure 18, lanes 5, 7 and 8). PKB (m/pPKB) and PI3-K (rCD2-p110) 
did not change BRF1 migration (lanes 3 and 4). Although p38 seems to be involved in arsenite-
induced BRF1 phosphorylation (Fig. 16) and the p38 downstream kinase MK2 has been shown to 
phosphorylate TTP, transfection of activated MK2 did not alter the migration of BRF1. 
Together, these data support the previous fi nding: In addition to PKB, also p38 (downstream 
of MEK6) and ERK (downstream of Raf) are able to phosphorylate BRF1 and PKB mediated 
phosphorylation does not affect the electrophoretic mobility of BRF1. Thus, this protein seems to be 
regulated via multiple pathways. Whether p38 mediated phosphorylation is direct or depends on any 
downstream factors, such as MK2, still remains to be elucidated. Although this set of experiments 
implicate that MK2 is not involved in BRF1 phosphorylation, it is diffi cult to compare different 
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Figure 18
Figure 18: myc-tagged 
pTRE-BRF1 was 
transfected together with 
activated kinases (m/pPKB, 
rCD2-p110, MEK6DD, 
MK2EE, RafCT) and 
rasV12 into NIH3T3 cells 
(B2A2 clone) and the 
electrophoretic mobility 
was analyzed by Western 
blot. (*Expression of BRF1 was changed upon cotransfection of the different kinases due to effects on the promoter. 
Therefore, lanes 1 and 2 were exposed longer for equal signal intensity.)
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In summary the data presented so far show that BRF1 is phosphorylated at S92 by PKB (Schmidlin 
et al., 2004) and, dependent on the cell, also by at least one other kinase, most probably ERK1 or 
2. In addition, BRF1 is also phosphorylated at site(s) different from S92 by kinase(s) from the p38, 
the MEK1/2 and/or the PKC pathway. In the case of insulin stimulation in HIRc-B cells, mainly the 
MEK pathway seems to be involved, whereas in the arsenite-treated NIH3T3 cells also p38 seems 
to play a role. The functional signifi cance of these diverse phosphorylation events still remains to be 
elucidated. However it is likely that, in vivo, inactivation of BRF1 requires more than one signal.
Mutational Analysis of Putative MK2 Sites
The putative phosphorylation sites (see Figure 8) were now studied in more detail. Publications 
by Chrestensen, Stoecklin and 
coworkers (Chrestensen et al., 
2003; Stoecklin et al., 2004) 
proposed a role for MK2 in TTP 
phosphorylation at serines 54 
and 178. This phosphorylation 
inactivates TTP, probably, through 
binding to 14-3-3. Comparison 
of the TTP and the BRF1 protein 
sequence revealed S203 in BRF1 
as the homologues site of one of 
the two MK2 phosphorylation sites 
in TTP (S178) (Figure 19). All the 
putative phospho-sites of BRF1 
are conserved in BRF2, whereas 
none of these sites, except S203, 
can be found in TTP. This implies 
that the three proteins despite their 
homology are differently regulated. 
Further, S203 and its neighboring 
amino acids seem to be a common 
motif of all three mammalian Tis11 
        1                                                   50
BRF1    MTTTLVSATI FDLSEVLCKG NKML.NYSAP SAGGCLLDRK AVGTPAGG..
BRF2    MSTTLLSA.F YDV.DFLCKT EKSLANLNLN N....MLDKK AVGTPVAAAP
TTP     ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~
        51          S54                                    100      
BRF1    ......GFPR RHSVT..... ...LP..... SSKF....HQ NQLLSS...L
BRF2    SSGFAPGFLR RHSASNLHAL AHPAPSPGSC SPKFPGAANG SSCGSA...A
TTP     ~~~~~~~~~~ ~~~~~~~MDL TAIYESLLSL SPDVPVPSDH GGTESSPGWG
        101                                   S92          150      
BRF1    KGEP...... .......APA LSSRDSRF.. .RDRSFSEGG ER...LLP..
BRF2    AGGPTSYGTL KEPSGGGGTA LLNKENKF.. .RDRSFSENG DRSQHLLH..
TTP     SSGPWSLSPS DSSPSGVTSR LPGRSTSLVE GRSCGWVPPP PGFAPLAPRL
        151                                                200      
BRF1    ...TQKQP.. .GGGQVNSSR YKTELCRPFE ENGACKYGDK CQFAHGIHEL
BRF2    ...LQQQQKG GGGSQINSTR YKTELCRPFE ESGTCKYGEK CQFAHGFHEL
TTP     GPELSPSPTS PTATSTTPSR YKTELCRTFS ESGRCRYGAK CQFAHGLGEL
        201                                                250      
BRF1    RSLTRHPKYK TELCRTFHTI GFCPYGPRCH FIHNAEERR. ALAG..ARDL
BRF2    RSLTRHPKYK TELCRTFHTI GFCPYGPRCH FIHNADERRP APSGGASGDL
TTP     RQANRHPKYK TELCHKFYLQ GRCPYGSRCH FIHNPSE... ........DL
        251                       S203                     300      
BRF1    SA........ ......DRPR LQHSFSFAGF PSA......A ATAAATGLLD
BRF2    RAFGTRDALH LGFPREPRPK LHHSLSFSGF PSGHH..QPP GGLESPLLLD
TTP     AAPGHP.... ........PV LRQSISFSGL PSGRRTSPPP PGLAGPSLSS
        301    T227                                        350      
BRF1    ...SPTSITP PP........ .......... .......... ..........
BRF2    ...SPTSRTP PPPSCSSASS CSSSASSCSS ASAASTPSGA PTCCASAAAA
TTP     SSFSPSSSPP PPGDLPLSPS AFSAAPGTPL ARRDPTPVCC PSCRRATPIS
        351                                                400      
BRF1    ....I..L.. ..SADDLL.. GSP....TLP DGTNNPFAFS SQELA...SL
BRF2    AAAAL..LYG TGGAEDLLAP GAPCAACSSA SCANNAFAF. GPELS...SL
TTP     VWGPLGGLVR TPSVQSLGSD PDEYASSGSS LGGSDSPVFE AGVFAPPQPV
        401                                                450      
BRF1    .......... FA........ .......... .......... PSMGLPGGGS
BRF2    ITPLAIQTHN FAAVAAAAYY RSQQQQQQQG LAPPAQPPAP PSATLPAGAA
TTP     AAPRRLPIFN RISVSE~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~
        451            S283        S294                    500      
BRF1    .....PTTF. LFRPMSESPH MFDSPPSPQD SLSDQEGYLS S..SSSSHSG
BRF2    APPSPPFSFQ LPRRLSDSP. VFDAPPSPPD SLSDRDSYLS GSLSSGSLSG
TTP     ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~
        501                     523                            
   
BRF1    SDSPTLDNSR RLPIFSRLSI SDD
BRF2    SESPSLDPGR RLPIFSRLSI SDD
TTP     ~~~~~~~~~~ ~~~~~~~~~~ ~~~
Figure 19: Alignment of the protein 
sequence of the three human Tis11 
family members BRF1, BRF2 and TTP 
(SwissProt accession number Q07352, 
P47974 and P26651, respectively) . 




family members. Based on this homology, S203 and the other putative MK2 site S283 were further 
analyzed.
Mutants were constructed, where S203 or S283 were replaced by alanine, yielding BRF1S203A 
and BRF1S283A (see Materials and Methods). These constructs were used to check, whether 
mutation of these sites has an effect on the migration of BRF1. The mutants were transfected into 
HIRc-B cells and stimulated after 24h with insulin. The Xpress-tagged protein was detected by 
Western blotting using the respective antibody (Invitrogen®). As seen before, insulin did induce an 
upshift of BRF1 protein (Figure 20, compare lanes 1 and 3, upper panel). This shift was reduced by 
dephosphorylation of the protein by λ-PPase (lanes 2 and 4) and, therefore, due to phosphorylation. 
As a control for the insulin stimulation and the dephosphorylation reaction, phospho-ERK1/2 was 
visualized on the same blot (lower panel). Interestingly, no upshifted, phosphorylated form of the 
BRF1S203A mutant could be detected, neither in untreated nor in insulin stimulated cells (Figure 
20, lanes 5-8). Mutation of S283 (lanes 9-12), on the other hand, showed no difference compared 
to wild-type BRF1 in respect to migration. This set of data shows that S203 is phosphorylated in 
vivo.
For the last set of experiments presented in this section, I would like to acknowledge Min Lu for 
technical assistance. S203 seems to be an in vivo site for BRF1 phosphorylation. To further examine 
the functional signifi cance of this site, recombinant mutant BRF1 was tested in an in vitro decay 
assay as described in (Schmidlin et al., 2004). Addition of BRF1 mutated at S203 (BRF1S203A) 
alone or at S90, 92 and 203 (BRF1S90/92/203A) to slowC extracts was able to induce degradation 
of ARE-mRNA similar to BRF1wt. Mutation of S203 did not disturb the decay promoting activity 
of BRF1 in this assay. 
To test, whether phosphorylation at S203 inhibits BRF1 decay promoting activity similar to S92, 
BRF1S203A and the dox-regulable β-globin-IL3 reporter (used in Figure 13A) were cotransfected 
alone or in combination with activated kinases m/pPKB and/or MK2EE into NIH3T3 cells, stably 
expressing the tTA transactivator (B2A2, (Xu et al., 1998)/ see Figure 12 for a summary of the Tet-Off 
system). Transcription of the reporter was turned of by addition of dox and its stability was investigated 
by northern analysis. In contrast to the in vitro data (Schmidlin et al., 2004), in vivo, BRF1wt partly 
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into HIRc-B cells. 
Where indicated, 
cells were treated 
with insulin for 15min before harvesting. After λ-PPase-treatment samples were processed for Western blotting and the 
Xpress-tagged BRF1 (Xpress-BRF1) and activate ERK1/2 (pERK1/2) were visualized by immunoblotting.
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completely inactivated and the ARE-reporter is stable (Sabrina Leuenberger, PhD thesis, 2004).
If phosphorylation of S203 is involved in this inactivation, the BRF1S90/92/203A triple mutant 
is expected to withstand this inactivation. Indeed, also in the presence of both, activated PKB 
and MK2, reporter RNA is still rapidly degraded, if the BRF1S90/92/203A was cotransfected. 
Keeping in mind that S203 is homologous to a known MK2 site in TTP and BRF1S90/92/203A 
is refractory to PKB/MK2 induced inactivation in decay assays, MK2 seems to be responsible 
for S203 phosphorylation. However, BRF1S90/92/203A was also resistant to m/pPKB-mediated 
inactivation, whereas BRF1S90/92A and BRF1S203 were only partly inhibited. This argues that 
S203 is also regulated by PKB. Further, BRF1S203A does not upshift on SDS-PAGE as compared 
to BRF1wt, an upshift, which is inhibited by the MEK inhibitor UO126. 
To clarify, whether phosphorylation of S203 is mediated by PKB, MK2 or ERK1/2, in vitro kinase 
assays were performed, where rBRF1wt and rBRF1S203A were incubated with activated PKB 
(Schmidlin et al., 2004), ERK1 (Upstate, #14-439) or with activated p38 alone or together with 
MK2 (kindly provided by Hermann Gram, Novartis). All tested kinases did phosphorylate rBRFwt. 
To our surprise, BRF1S203A phosphorylation was comparable to BRF1wt phosphorylation under 
all tested conditions. One possibility is that in this assay BRF1 becomes phosphorylated at (artifi cial 
or physiological) sites different from S203, covering a possible difference between BRF1wt and 
BRF1S203A. This matter will have to be analyzed in more detail.
Taken together, during these studies, S92 could be identifi ed as major PKB phosphorylation site in 
vitro and in vivo. In addition strong evidence for S203 as a phosphorylation site could be accumulated. 
Both sites seem to be involved in inactivation of BRF1. However, the kinase(s) responsible for S203 
phosphorylation and the additional kinase phosphorylating S92 could not be identifi ed yet. 
Subcellular Localization of AU-Binding Proteins
Control of protein localization is one way to regulate protein function. For all four AUBPs investigated 
in this part (HuR, AUF1
p37
, TTP and BRF1), nucleo-cytoplasmic shuttling has been reported before 
and during these studies (Fan and Steitz, 1998; Murata et al., 2002; Phillips et al., 2002; Sarkar 
et al., 2003). The predominant nuclear localization of HuR, the best-studied example, changes 
during cell cycle progression (Wang et al., 2000a). During late G1, early S and during G2 phase the 
cytoplasmic portion of HuR increases. HuR export parallels stabilization of cyclin A and B1 mRNA. 
In response to UV-irradiation, cytoplasmic HuR levels are also elevated, favoring stabilization of 
cyclin-dependent kinase inhibitor p21 (Wang et al., 2000b) and the small G-protein RhoB mRNA 
(Westmark et al., 2004). The Tis11 protein family members contain a leucine-rich nuclear export 
signal that interacts with the nuclear export receptor CRM1. These proteins are nucleo-cytoplasmic 
shuttling proteins and rely on CRM1 for their export from the nucleus. (Murata et al., 2002; Phillips 
et al., 2002). Diverse shuttling has been reported for the 4 different AUF1 isoforms. Nuclear export 
seems to be facilitated by sequences in exon 7, only found in the C-terminal domain of the two larger 
AUF1 isoforms (Sarkar et al., 2003). These fi ndings suggest possible roles for nuclear import and 
export in the regulation of AUBP activity. Therefore, in the second part of this work, the subcellular 
localization of the four AUBPs mentioned above was investigated and the question was asked, 
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Figure 21: Localization of HuR in NIH3T3 cells. A: HuR (immunofl uorescence using mouse monoclonal anti-HuR is 
shown in red) is predominantly localized in the nuclei (DAPI stain in blue), except in mitotic cells (arrows) B: Upon 
entry in mitosis HuR is rapidly exported into the cytoplasm. Cells at different stages of mitosis were stained for HuR 
and the corresponding phase contrast picture is shown. C: Triple staining of a representative cell in metaphase showing 




Endogenous HuR. First, localization of HuR in NIH3T3 mouse fi broblasts was analyzed by 
immunofl uorescence using a monoclonal HuR antibody (3A2). A strong nuclear staining could be 
observed (Figure 21A). In 1-2% of the cells, HuR was present in the cytoplasm (Figure 21A, see 
arrows). Further analysis of the cells with cytoplasmic HuR staining revealed that they were entering 
mitosis, as seen by the beginning condensation of the chromosomes stained with 4’,6-diamidino-2-
phenylindole (DAPI). Figure 21B shows NIH3T3 cells at different stages of mitosis stained for HuR 
(panel 1: prophase, 2: late metaphase, anaphase, 3: anaphase 4, 5, 6: telophase). In the phase contrast 
next to the immunofl uorescence picture, the condensed chromosomes can be seen. During the early 
stage of prophase, HuR is exported from the nucleus and accumulates at the border of the nuclear 
structure (Figure 21B, panel 1) that is still maintained at this stage of mitosis (see (Aitchison and 
Rout, 2002) for review on nuclear envelope during mitosis). Accumulation of HuR in the cytoplasm 
is, therefore, not just the result of the dissolving nuclear membrane. 
The localization of HuR during prophase and metaphase resembles the mitotic spindle. Therefore 
co-localization of HuR with tubulin, a component of this structure (Karsenti and Vernos, 2001), 
was performed.As seen in Figure 21C, no co-localization could no observed. Whether the export 
of HuR is of any physiological signifi cance with respect to stabilization of mitosis-regulating 
transcripts, or whether it only assures even redistribution of the protein after cytokinesis was not 
further investigated. The fact that the export takes place at the onset of mitosis, when the nuclear 
structure is still maintained, suggests that HuR is actively exported from the nucleus and that this 
distribution is of some signifi cance during mitosis. However, experiments with control markers for 
mitosis were not performed, as the time window of this HuR export is very narrow and it would 
be diffi cult to obtain further insight into this phenomenon. Cell cycle dependent changes of HuR 
localization have been reported by Wang et al. (Wang et al., 2000a), where stabilization of cyclins A 
and B1 was paralleled by cytoplasmic accumulation of HuR. This cytoplasmic accumulation of HuR 
peaked during S phase and HuR was found to reenter the nucleus in G2. In addition, the proportion 
of cytoplasmic HuR was never higher than 25% of total protein as measured by Western blot. The 
two phenomena are therefore not directly linked. 
myc-HuR: As lined out before, several signaling pathways are known to be involved in stabilizing 
mRNA. Further, localization of AUBPs seems to be important for their function. Therefore, the 
hypothesis was tested, whether signaling pathways directly infl uence the localization of AUBPs 
and, thereby, regulate their function. To study this for HuR, myc-tagged HuR was cotransfected 
together with activated kinases of interest into NIH3T3 cells and the subcellular localization was 
analyzed by immunofl uorescence against the myc-tag. Similar to the endogenous HuR, myc-HuR 
localized to the nucleus (Figure 22A). If activated MEK6 (MEK6DD) was cotransfected together 
with HuR (Figure 22B), an increase in cytoplasmic HuR levels could be detected. Upon inhibition 
of MEK6 downstream signaling by the presence of dominant negative p38 MAPK (p38-AGF), HuR 
stayed in the nucleus (Figure 22C). Export is, therefore, mediated via p38. In this case, a correlation 
between stabilizing conditions (Ming et al., 2001) and cytoplasmic accumulation of HuR could be 
observed, strengthening the hypothesis that HuR export from the nucleus plays a role in protecting 
ARE-mRNA from degradation. 
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Our lab has also reported that 
the PI3-K pathway stabilizes 
ARE transcripts (Ming et al., 
2001). A constitutively active 
form of PI3-K, where the 
cytoplasmic domain of the 
rat CD2 (rCD2) cell-surface 
antigen was replaced by the 
catalytic p110 domain of PI3-K 
(rCD2-p110) (Reif et al., 
1996) was transfected together 
with HuR into NIH3T3 
cells. Similar to MEK6DD, 
activation of the PI3-K 
signaling pathway increased 
the levels of cytoplasmic 
HuR (Figure 22F). This 
export was not affected by the 
presence of dominant negative 
p38-AGF (Figure 22G), arguing that the mechanism leading to MEK6DD induced cytoplasmic 
accumulation is different from the one induced by rCD2-p110. Inhibition of PI3-K by WM was 
able to block the PI3-K mediated export of HuR (Figure 22H), but had no effect on MEK6DD 
(Figure 22D). PKB, a downstream kinase of PI3-K, was also tested. Its stabilizing effect has been 
discussed in the previous chapter (Schmidlin et al., 2004). Cotransfection of HuR together with
m/pPKB did not alter the predominant nuclear localization of HuR (Figure 22E). Thus, the PI3-K 
induced change of HuR localization is not mediated by PKB. As seen in (Schmidlin et al., 2004), 
PKB does phosphorylate and, thereby, inactivate BRF1, leading to stabilization of ARE-mRNA. 
















































Figure 22: Cotransfection of myc-
HuR (pcDNA3.1-HuR-HIS/myc) 
together with activated or dominant 
negative kinases as indicated. 
Localization of myc-HuR was 
analyzed by immunofl uorescence 
directed against the myc-tag. 2 
different cells are shown for each 




12-O-tetradecanoyl-13-phorbol acetate (TPA)-treatment, activating protein kinase C (PKC) is 
another stimulus, which is known to stabilize ARE-mRNA (Hahn and Moroni, 1994). Cells treated 
with TPA do also accumulate HuR in the cytoplasm (data not shown). Another drug tested was 
ActinomycinD (ActD), as it is routinely used to inhibit transcription in mRNA turnover assays. Also 
treatment of cells with ActD was found to rapidly export HuR from the nucleus (data not shown). 
This effect has been published by Atasoy et al. (Atasoy et al., 1998).
GFP-HuR: To track HuR in a living cells, green fl uorescent protein - HuR fusion protein was 
constructed (GFP-HuR; see Materials and Methods, Figure 33A) and expressed in NIH3T3 cells. 
The GFP-HuR protein behaved similar to the myc-tagged HuR under all tested conditions. However, 
the differences observed were smaller. Although the nuclear localization signal of HuR was able to 
accumulate the otherwise cytoplasmic GFP in the nucleus, shuttling might be hindered to some 
extent by the large GFP protein. It was hard to detect differences in localization upon cotransfection 
of kinases (data not shown). Nevertheless, HuR localization could be visualized in living cells, 
and again a predominant nuclear localization could also be seen. GFP-HuR was followed in single 
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Figure 23: ActinomycinD time course. Localization of GFP-HuR in a living NIH3T3 cell was followed in 10min time 
intervals after administration of ActinomycinD (5µg/ml).
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cells in 10 minutes time intervals after ActD-treatment. An enrichment of cytoplasmic HuR could 
be observed over time (Figure 23). HuR was chased out of the nucleus already after 30 minutes. If 
GFP-HuR relocalization to the cytoplasm is indeed affecting mRNA stability, the results from ActD-
chase experiments to measure mRNA half-lives have to be interpreted carefully.
In the following table the immunofl uorescence data is summarized in a qualitative way: From all 
the experiments performed, the results were classifi ed into strong export (++), intermediate export 
(+) and no export (-). Strong export was attributed, if 25-50% of the protein was exported into the 
cytoplasm, as estimated by immunofl uorescence. 
AUF1
myc-AUF1: As our AUF1 antibody did not perform well in immunofl uorescence studies, 
localization of exogenous AUF1
p37
 was followed in a similar set of experiments as described for 
HuR. myc-tagged AUF1
p37
 was transfected alone or in combination with activated kinases into 
������� �������
������ ���� ������������ � ������������ �
� �� � �
���� �� � �� �
��� �� � � �
���� � � ����
��� � � ����
��������� � � ����
��������� �� � � �
��������� ���������� � � ����
��������� ��������� �� � ����
����������������� � � ����
������ �� � � �
������ ���������� �� � ����
������ ��������� �� � ����
�������������� � � � �
������������ �� � ����
������� � � ����
������� ���� �� � ����
��� � � ����
����� �
���� ������� �� ������������ ������� ��������� ������
Table 4: Summary of immunofl uorescence data of HuR
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NIH3T3 cells and the subcellular localization of the protein was analyzed with immunofl uorescence 
against the myc-tag. AUF1 behaved similar to HuR under all tested conditions: In unstimulated cells 
AUF1
p37
 was localized mainly in the nucleus. Activation of the p38 MAPK pathway (MEK6DD) as 
well as the PI3-K (rCD2-p110) pathway induced export of the protein. Also TPA- or ActD-treatment 
led to export of AUF1
p37
. m/pPKB did not change the nuclear localization of AUF1
p37
.The data is 
summarized in table 5 again in a qualitative way. In NIH3T3 cells, the same stimuli inducing export 
of HuR did also lead to export of AUF1
p37
 from the nucleus. Overall, the data obtained with AUF1
p37
were less conclusive than the results with HuR, as the detected differences were smaller. The parallel 
export of AUF1
p37
 and HuR may point towards a collaboration of these two RNA binding factors in 
stabilizing specifi c sets of mRNA. However, it was not investigated, whether the two AUBPs are 
also co-regulated in other cells, where AUF1 has been shown to function as a RNA destabilizing 
protein. Further, it would be interesting to investigate, whether localization of the four different 
isoforms is regulated differently.
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Table 5: Summary of immunofl uorescence data of AUF1
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GFP-AUF1: To investigate the localization of AUF1
p37
 in living cells, a GFP-AUF1
p37
-fusion protein 
was constructed (Figure 33B). In transfected cells GFP-AUF1
p37
 localization was similar to the myc-
AUF1
p37
 protein, but again the differences observed between the tested conditions were smaller (see 
table 5). Therefore, the GFP-AUF1
p37
 construct was used to followed AUF1 localization in living 
cells. GFP-AUF1
p37
 localization was predominantly nuclear. Upon ActD-treatment, AUF1
p37
 was 
effi ciently exported from the nucleus, as seen in a time course of one single cell over 2h (Figure 
24).
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Figure 24: ActinomycinD time course. Localization of GFP-AUF1p37 in NIH3T3 cells was followed in 10min time 




To obtain high levels of myc-tagged TTP, it was expressed from a tetracycline controllable CMV 
promoter (pTRE-TTP). With this system constant overexpression of TTP with possible toxic effects 
(Johnson et al., 2002) could be avoided, as TTP can be induced shortly before analysis. Transfection 
of pTRE-TTP into B2A2 cells, stably expressing the tTA transactivator (Xu et al., 1998), resulted 
in high expression of myc-TTP, which could be visualized by immunofl uorescence. TTP was 
found to be present in both, the nucleus and the cytoplasm in unstimulated cells (Figure 25 and 
(Stoecklin et al., 2002)). The distribution was about 1:1 with substantial variation. The localization 
of TTP probably is affected by the cell cycle or the 
stress states of the cells, which might explain the 
variations observed. 
BRF1
Similar results to TTP were obtained in the 
case of BRF1. Myc-BRF1 expressed from 
the same promoter as TTP (pTRE-BRF1) 
was found in the nucleus and the cytoplasm
(Figure 25 and (Stoecklin et al., 2002)). Staining 
for the endogenous BRF1 with a rabbit anti BRF1 
antibody (Raineri et al., 2004) confi rmed the 
equal distribution (data not shown). However, 
this staining may to some extent arise from BRF2, 
which is also recognized by this antibody and is 
very abundant in unstimulated cells. 
The subcellular distribution of TTP and BRF1 did 
not allow to monitor changes in their localization 
upon external stimuli or upon activation of 
signaling cascades. As already a substantial portion 
of the proteins were present in either cellular 
compartment and some variability was detected, 
changes are not likely to signifi cantly infl uence 
function. However, it cannot be ruled out that 




Figure 25: NIH3T3 cells were transfected with pTRE-
BRF1, pTRE-TTP together with the transactivator tTA 
(pTet-Off) or HuR alone (pcDNA3.1-HuR-HIS/myc) and 
the subcellular localization of the proteins was visualized by 
immunofl uorescence. Two representative pictures with the 
respective phase contrast picture to the right are shown. 
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localization affect function. Due to the small differences detected in the case of the predominantly 
nuclear proteins HuR and AUF1
p37
 and the variability of TTP and BRF1 localization in unstimulated 
cells, no further studies were performed to clarify this matter.
Taken together, the experiments above indicate, that the two mRNA stabilizing proteins HuR and 
AUF1
p37
 are co-regulated in NIH3T3 cells. They are stored in the nucleus and are exported to 
the cytoplasm, upon activation of the stabilizing p38 and PI3K pathways. In the cytoplasm they 
stabilize ARE-mRNA. The two destabilizing proteins TTP and BRF1 are present in the cytoplasm, 
where they can promote constitutive degradation of transcripts. Inhibition of this degradation may 
either be achieved by phosphorylation and concomitant change of binding partners (see (Schmidlin 
et al., 2004)) or by competition with the stabilizing AUBPs, which accumulate in the cytoplasm in 
response to mRNA stabilizing stimuli.
Physiological Role of BRF1
BRF1 was functionally cloned in our lab as an ARE-mRNA destabilizing factor. However, very little 
is known about the physiological role of this protein and its target messages. One report shows an 
apoptotic effect of BRF1 overexpression (Johnson et al., 2000). On the other hand, high levels of 
BRF1 expression have been found in t(8;21) leukemic cells. Overexpression of BRF1 in myeloid 
progenitor cells (L-G) induced myeloid cell proliferation and delayed differentiation in response 
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Figure 26: A: Testing of BRF1 expression in different clones. Puromycin resistant clones were grown in the presence 
of dox (+/ 2µg/ml) and dox was removed overnight, where indicated (-). BRF1off11 and 14 (lanes 9, 10 and 13, 14 
respectively) were used for further experiments. B: Time course of BRF1 repression and induction in BRF1off11. Cells 
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to granulocyte colony-stimulating factor (G-CSF). These results suggest that the high expression 
of BRF1 contributes to AML1-MTG8-mediated leukemogenesis (Shimada et al., 2000). These 
data show a dual role of BRF1 in both, apoptosis and cell proliferation. To further understand this 
controversial set of data, the effect of BRF1 expression was studied in NIH3T3 cells.
Construction of a Doxycycline-Repressible Cell Line
As mentioned above, BRF1 might induce apoptosis and might therefore be toxic, when 
overexpressed. A system was required, where BRF1 expression could be turned on in a given time 
window. This was achieved by constructing a doxycycline (dox) / tetracycline (tet) inducible cell 
line (Gossen and Bujard, 1992), which would allow to study BRF1 effects in a monoclonal situation 
and should circumvent any possible toxic effect of BRF1 overexpression. The Tet-Off system has 
already been introduced in Figure 12.
B2A2 cells stably express the tTA transactivator (Xu et al., 1998). Into a subclone from this cell 
line (clone 23) BRF1 was transfected under the control of the tet-responsive promoter described 
above (pTRE-BRF1 see Materials and Methods) together with a plasmid carrying a puromycin 
resistance gene (pMX-puro) in a 10 to 1 ratio. The transfected cells were selected with puromycin 
(2µg/ml). Surviving cells were tested by Western blot analysis for dox repressible BRF1 expression. 
The clones were grown in the presence of dox. 16h after dox removal, the cells were harvested and 
BRF1 expression was analyzed. 2 clones (named BRF1off11/BRF1off14) with low background and 
strong induction of BRF1 expression were used for further analysis (see Figure 26A, lanes 9, 10 
and 13, 14). If the cells were grown in absence of dox, the high BRF1 expression could be turned 
down within 4h after addition of dox (Figure 26B, lanes 1-4). Cells grown in the presence of dox 
expressed background levels of BRF1, which could be further induced by removal of dox (Figure 
26B, lanes 5-8). The longer exposure of the Western blot revealed some leaky expression of BRF1 
also in the presence of dox.
Role of BRF1 in Cell Cycle Control
Many cyclin and growth factor mRNAs contain AREs in their 3’UTR, which makes them putative 
targets for BRF1 mediated degradation. Therefore, it seemed plausible to ask, whether BRF1 levels 
play a role in cell cycle control. The cell cycle distribution of cells was analyzed by staining cells 
with propidium iodide (PI), a DNA intercalating dye, giving a fl uorescent signal proportional to 
the DNA content. By fl uorescence assisted cell scan (FACS), the signal intensity was measured. To 
analyze changes in the cell cycle distribution, cells needed to be synchronized. This was done by 
serum-starvation. 24h after FCS-removal, approximately 90% of the cells accumulated in G0/G1. In 
Figure 27, panel 1 a normal distribution of untreated B2A2 cells can be seen. After starvation, only 
one population of NIH3T3 cells corresponding to G0/G1 cells could be detected (panel 2). Upon 
addition of 10% serum, the cells started to progress through the cell cycle synchronously, entering S 
phase after approximately 16h (Figure 27 panel 3, reduced height of the G0/G1 peak) and reaching 
G2 after about 20-24h (panels 4 and 5). The presence of dox did not affect the synchronization, as 
the green line (no dox) overlaps with the blue curve (plus dox). 
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With this synchronization protocol established in NIH3T3 cells, cell cycle progression of the BRF1 
overexpressing cells was now analyzed in the presence or absence of dox, resulting in lower or higher 
levels of BRF1 respectively. The BRF1off11 and BRF1off14 cells were passaged in presence of dox 
and dox was removed, where mentioned, when the cells were splitted for the experiment 24h before 
starvation. BRF1off11 or BRF1off14 cells were starved for 24h and the G0 arrest was subsequently 
released by the addition of 10%FCS in presence (repression of BRF1 expression) or absence of dox 
(BRF1 overexpression). After starvation (Figure 28, panel 2), a high percentage of the cells were in 
G0/G1. In the absence of dox (green line) the cells entered the S phase more rapidly than the control 
cells (Figure 28, panels 3-6: the shoulder to the right of the G0/G1 peak, representing the S phase 
cells, appears faster, and the G0/G1 population is reduced more quickly in absence of dox). This 
effect was consistently observed in both cell lines tested and was absent in the control B2A2 cell 
line (Figure 27 panels 3-5), arguing that overexpression of BRF1 is driving G0/G1 to S transition. 
However, the difference, although reproducible, was rather small, with a maximum of about 20% 







































































































Figure 27: FACS profi les of B2A2 cells stained with PI in absence (green line) or presence of dox (blue curve). G1: 
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Figure 28: FACS profi les of BRF1off14 cells stained with PI in absence (green line) or presence of dox (blue curve). 
G1: Cells in G1 phase; G2/M cells in G2/M phase; Untr.: untreated cells; st. 24: starved for 24 h; FCS: addition of FCS 
for indicated hours. 
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To further confi rm this observation, BRF1 was 
downregulated by RNAi. siRNA directed against 
nucleotides 130-148 of BRF1 or nucleotides 245-263 of 
the unrelated β-globin were transfected by lipofection 
into NIH3T3 cells. 24h after transfection, FCS was 
removed for another 24h to synchronize the cells. At 
this time point, RNA was extracted to measure the 
amount of BRF1 message by northern blotting (Figure 
29A). Compared to the β-globin transfected extracts, 
siRNA against BRF1 was able to downregulate mRNA 
levels of BRF1 (25% reduction, if standardized to the 
GAPDH loading control). After release of the cells from 
starvation, the cell cycle progression was analyzed as 
before. Downregulation of BRF1 slowed down the 
transition of 3T3 cells from G0/G1 to S phase compared 
to the negative control β-globin, seen best 22h after 
starvation (Figure 29B, siRNA against BRF1 is shown 
with the green line). However, the effect observed 
was minimal. This could be explained by the fact, that 
downregulation of BRF1 was not very effi cient and 
transfection followed by starvation led to a substantial 
number of dying cells, with mostly untransfected cells, 
which survived. This is also the reason, why not enough 
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Figure 29: A: BRF1 and GAPDH mRNA levels were measured 
by northern blot analysis 48h after transfection of siRNA against 
BRF1 or β-globin. B: B2A2 cells transfected with siRNA against 
β-globin or BRF1. After 24h the cells were starved for another 
24h before 10% FCS was added for indicated time periods. FACS 
profi les of the PI stained 
cells are shown. G0/G11: 
Cells in G0/G1 phase; 
G2/M cells in G2/M phase; 
Untr.: untreated cells; 
st. 24: starved for 24 h; 




To confi rm the above result, the effect of BRF1 overexpression in BRF1off11 or BRF1off14 cells 
on [3H]-thymidine incorporation was investigated. This method allows to quantify the amount 
of ongoing DNA synthesis. In this assay no statistically signifi cant difference could be detected, 
dependent on BRF1 levels (data not shown). 
Taken together, the experiments indicate that BRF1 at high levels accelerates the transition of 
NIH3T3 cells from G0/G1 to S phase, whereas reduced levels seem to have the opposite effect. 
The differences observed were reproducible but minimal, making it diffi cult to further investigate 
this phenomenon. It cannot be stated, whether this effect is due to destabilization of a specifi c set of 
ARE-mRNAs, which inhibit cell cycle progression, or whether the effect seen is indirect. Due to the 
mentioned diffi culties this project was discontinued at this stage.
Overall, weak evidence is presented in this thesis that BRF1 is involved in cell cycle progression, 
but no clear conclusions on the physiological role of BRF1 can be drawn, based on these data. The 
work on regulation of BRF1 activity was more successful. Two regulatory sites could be identifi ed 
in BRF1 (S92 and S203). Together with the localization data of HuR, these fi ndings provide us with 




Regulation of BRF1 Activity by Different Signaling Pathways
In this work, different aspects of AU-binding protein regulation and function were analyzed. These 
proteins are involved in the turnover of ARE-containing mRNA. Today only few AUBPs are known 
(see table 3, introduction), but analysis of the human genome revealed that approximately 8% of all 
mRNAs contain an AU-rich element in their 3’UTR (Bakheet et al., 2001). How does a cell control 
the stability of so many transcripts, encoding functionally completely diverse proteins, with only a 
handful of binding proteins? In addition, some of these AUBPs seem to have only a restricted set 
of target mRNAs, as shown by the TTP knockout mouse, in which only stabilization of GM-CSF 
and TNFα message was detected (Taylor et al., 1996; Carballo et al., 2000). One solution to this 
problem might be that, in addition to the ARE, secondary elements play a role. This hypothesis is 
strengthened by the fact that it is not possible to deduce the activity of an AU-rich element based 
on its primary sequence. Further, a growing number of AUBP-interacting proteins and signaling 
pathways modifying the AUBP function shed light on the complex regulatory network, which is 
needed to precisely control activity and specifi city of the AUBPs. The goal of this work was to better 
understand this regulation of AUBP activity with focus on BRF1. 
PKB phosphorylates BRF1 at S92. BRF1 has been functionally cloned in our lab (Stoecklin et 
al., 2002) and has been shown to promote ARE-dependent mRNA degradation in vitro and in vivo. 
According to its protein sequence, BRF1 contains multiple putative phosphorylation sites, where 
its activity might be regulated (Figure 8). Among others, BRF1 contains two overlapping PKB 
consensus sites at S90 and S92. By mass spectrometry, S92 was confi rmed to be phosphorylated 
by PKB (Schmidlin et al., 2004). However, these data were obtained, using recombinant BRF1 
phosphorylated in vitro. To confi rm that S92 phosphorylation is physiologically relevant, an antibody 
was raised against a phospho-peptide spanning the region of S92 (Figure 9/10). With this antibody, 
phosphorylation of endogenous BRF1 was investigated. Indeed, S92 phosphorylation could also 
be detected in vivo after transfection of activated PKB (m/pPKB). Also PKB activation by a more 
physiological stimulus, such as insulin, can trigger phosphorylation of BRF1 at S92, indicating that 
this site is a PKB target in vivo. PKB activation of insulin was very poor in NIH3T3 cells. Therefore, 
BRF1 phosphorylation was also investigated in HIRc-B rat fi broblast cells, overexpressing the 
human insulin receptor. In these cells, a prominent S92 phosphorylation could be detected upon 
insulin stimulation. Although BRF1 expression was found to be induced by insulin (Corps and 
Brown, 1995), the concentration used in the experiments described in this thesis did not alter BRF1 
levels under the tested conditions.
82
DISCUSSION
A WM-insensitive kinase also phosphorylates BRF1 at S92. In contrast to NIH3T3 cells, where 
insulin induced PKB activation and phosphorylation of S92 in BRF1 is only weak, but WM-
sensitive, in HIRc-B cells S92 phosphorylation could only partly be inhibited by WM (Schmidlin et 
al., 2004). This suggests that, in addition to PKB, another kinase is likely to phosphorylate the same 
site. In the HIRc-B cells the response to insulin is much stronger than in NIH3T3 cells, as seen by 
the activation of PKB (compare Figures 10 and 15). In addition to the PKB pathway, in HIRc-B cells 
insulin stimulation also strongly activates other pathways, including the ERK1/2 and p38 pathways 
(Figure 15), leading to phosphorylation of BRF1 in a WM-insensitive manner. A single serine can be 
phosphorylated by more than one kinase. The nuclear factor CREB, for example, is phosphorylated 
at S133 by several different kinases, including PKA, PKB and other AGC kinases (Johannessen et 
al., 2004). In the case of S92 in BRF1, the additional kinase seems to be inhibited by the MEK1/
2 inhibitor UO126 (Figure 15), indicating that the downstream kinases ERK1/2 are involved in 
this phosphorylation event. S92 is not placed in the context of an ERK consensus site (Davis et 
al., 1993), which would require a proline following the phosphorylated serine. However, also the 
PKB consensus is not optimal (lacking a hydrophobic residue after the serine), but, nevertheless, 
phosphorylation by PKB is very effi cient. ERK target proteins have been found to share at least one 
of two common docking motif (Jacobs et al., 1999): the D-domain (K/R-X-X/K/R-K/R-X
(1-4)
-L/I-X-
L/I), which can be placed rather remote from the actual phosphorylation site, or the DEF site (F-X-
F-P) in the proximity of the phospho-site. Interestingly BRF2 contains a D-domain in its N-terminus 
(see Figure 19 (amino acids 17-27)), the Lysines being conserved in BRF1. Again, this pattern 
only serves as a hint and no proof, but it seems as if phosphorylation of S92 by ERK1/2 would be 
possible. However, further experiments need to be done to identify the respective kinase.
Phosphorylation of S92 inhibits the decay promoting activity of BRF1. In vitro decay experiments 
revealed that phosphorylation of S92 in BRF1 by PKB inhibits its decay promoting activity. 
Mutating S92 to alanine conferred resistance to this inactivation, showing that S92 is an important 
regulatory site. In addition, decay experiments in HIRc-B cells showed that, under conditions of 
BRF1 phosphorylation, such as transfection of activated m/pPKB or insulin stimulation, an ARE-
containing reporter transcripts and endogenous VEGF message are stabilized. Further, it could be 
shown that the insulin induced stabilization is dependent on PKBα, as in PKBα -/- cells, the ARE-
mRNA was generally less stable, and could not be stabilized upon insulin stimulation (Schmidlin et 
al., 2004). These data indicate that PKB mediated stabilization of ARE-mRNA involves inactivation 
of BRF1 by S92 phosphorylation.
BRF1 interacts with 14-3-3 in a phosphorylation-dependent manner. BRF1 inhibition seems 
to be accomplished by phosphorylation dependent binding of BRF1 to the scaffold protein 14-3-3. 
Interaction of 14-3-3 and BRF1 has already been reported by others (Bustin and McKay, 1999; 
Johnson et al., 2002) and was shown in our lab to depend on S92 phosphorylation: Recombinant 
BRF1 was able to pull down 14-3-3 from slowC cell extracts, only, if it was pre-incubated with 
PKB. Further, 14-3-3 could be co-immunoprecipitated together with exogenous BRF1 from COS7 
cells if S92 is phosphorylated (Schmidlin et al., 2004). In a very recent experiment, Brigitte Gross 
in our lab was able to co-immunoprecipitate endogenous 14-3-3 with a BRF1 antibody, for the fi rst 
time confi rming endogenous 14-3-3-BRF1 interaction. How the BRF1-14-3-3 interaction abolishes 
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the decay promoting activity of BRF1 is not known yet. Phosphorylation of BRF1 does not seem to 
affect binding of BRF1 to the mRNA (Schmidlin et al., 2004), neither does it alter the localization 
of BRF1 in the cell (data not shown). Probably, BRF1 coupled to 14-3-3 is no longer able to recruit 
the exosome to the mRNA. If BRF1 is still bound to mRNA in its inactive state, it might exert a 
stabilizing effect on the message, by hindering the exosome to access the transcript. If this is true, 
BRF1 may also be looked at as a stabilizing protein, which is turned into a destabilizing factor upon 
dephosphorylation. Experiments to clarify these points still need to be done. In the case of AUF1
p40
, 
phosphorylation changes the conformation of the bound mRNA, thereby, probably, altering the 
composition of the ribonuleo-protein complex (Wilson et al., 2003a; Wilson et al., 2003b). 
It has been reported by others that effi cient 14-3-3 binding requires two phospho-sites on a protein. 
In the case of TTP, phosphorylation of S54 and S178, both being targets of MK2, is required 
(Chrestensen et al., 2003; Stoecklin et al., 2004). It is very likely that BRF1, too, requires another 
phosphorylated site in addition to S92 for effi cient 14-3-3 binding. This idea is underlined by the 
fact that, in vivo, overexpressed BRF1 can only partly be inactivated by active PKB alone, but 
needs in addition at least one other kinase for full inactivation (see Figure 30). Eventually, under 
conditions of double phosphorylation BRF1-14-3-3 interaction is more stable. The existence of this 
second phospho-site still needs to be confi rmed and is the focus of ongoing work in our lab. 
BRF1 is phosphorylated at sites different from S92. BRF1 can be detected as multiple bands on 
Western blot. These bands represent different forms of BRF1, as they can be seen with exogenous 
BRF1, visualized with an antibody against a tag, and they are also found with endogenous BRF1. 
Upon arsenite stimulation of NIH3T3 cells and insulin-treatment of HIRc-B cells all bands are 
condensed to one slowly migrating form. Phosphatase-treatment reduces the different forms to 
one fast migrating band. These fi ndings, together with the multitude of putative phosphorylation 
sites found by bioinformatics and the fact that phosphorylation of BRF1 at S92 does not change 
the migration of BRF1 on Western blots, strongly suggest that BRF1 is phosphorylated also at 
sites different from S92. Interestingly, differently phosphorylated forms of BRF1 are present in 
unstimulated (and starved) cells. The function of these different forms of BRF1 is still a fi eld of 
speculation. Recently, it was shown in our lab that treatment of PB-3c mast cells with the Protein 
Phosphatase 2A (PP2A) inhibitor okadaic acid stabilizes ARE-containing reporter transcripts 
(Benjamin et al., 2004). Under these conditions BRF1 is hyperphosphorylated (Don Benjamin, 
unpublished data). One hypothesis, therefore, would be that fully phosphorylated BRF1 is inactive 
and might be activated by dephosphorylation. In unstimulated cells, a fraction of BRF1 protein is 
stored in an inactivated, phosphorylated state ready for rapid activation. It is also possible that the 
different phosphorylation forms exert different functions, by, e.g., blocking the access of the decay 
machinery to certain mRNA. Another possibility would be that differently phosphorylated BRF1 
populations target different sets of mRNAs. As shown in Figure 25, BRF1 is localized throughout 
the cell in unstimulated cells. Under the same conditions multiple phosphorylation forms of BRF1 
can be detected. Further, it has been reported that BRF1 localizes to stress granules upon arsenite-
treatment (Georg Stoecklin, personal communication). Therefore, localization of BRF1 might be 
regulated by phosphorylation.
Comparision of the protein sequence of all three Tis11 family members revealed only one conserved, 
putative phosphorylation site (Figure 19), namely S203 in BRF1. Therefore, S203 was mutated 
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to alanine (BRF1S203A). Interestingly BRF1S203A shows a different migration pattern from 
BRF1wt, lacking the hyperphosphorylated, slowly migrating band. Migration of the mutant does not 
change upon insulin stimulation in HIRc-B cells (Figure 20). These data strongly suggest that S203 
is an in vivo phosphorylation site of BRF1. Cotransfection decay assays confi rm the importance 
of S203: In contrary to the BRF1wt protein, the BRF1S203A can only partly be inactivated by 
combination of MK2EE and m/pPKB and the BRF1S90/92/203A triple mutant is resistant to this 
inactivation. This fi nding indicates that MK2 is the kinase responsible for S203 phosphorylation. 
However, the partial resistance of BRF1S90/92A to inactivation by PKB alone can be enhanced by 
mutating S203 in addition, indicating that PKB affects this site. Hence, the kinase responsible for 
S203 phosphorylation still remains to be identifi ed. The fact that rasV12 is still able to inactivate 
BRF1S90/92/203A indicates that there are even more sites, which play a role in inactivation of 
BRF1. 
Together, the data discussed here, suggest a model for BRF1 regulation, which is shown in Figure 
30: BRF1 exists in several differently phosphorylated forms. Activation of PKB, e.g. by insulin or 
another stimulus, leads to phosphorylation of BRF1 at S92. This event can be inhibited by WM. 
Upon insulin stimulation also ERK1/2 are activated and one of these kinases seems to phosphorylate 
BRF1 at S92 in a WM-insensitive way. Phosphorylated S92 displays a 14-3-3 binding consensus (R-
S-X-pS-X-P) (Tzivion and Avruch, 2002), missing only the P at position +2. Phosphorylation of S92 
leads to interaction of BRF1 with 14-3-3. 14-3-3 is known to bind as a dimer to 2 phospho-serine/
threonine motifs. Therefore, the interaction is probably strengthened by a second phosphorylation 
event, as it has been reported for TTP. In addition to S92, also S203 is a phosphorylation site. In 
TTP, phosphorylation of the homologues site to S203 was shown to be mediated by MK2 and 
enhance 14-3-3 binding (Stoecklin et al., 2004). Whether the same is true for S203 in BRF1 remains 
to be investigated. S203 is not placed in the context of a 14-3-3 binding motif, however, also the 
homologues site in TTP is not, and still, binding could be shown. Further, BRF1 is likely to be 
phosphorylated also at sites different from S92 and S203. Data obtained from insulin (Figure 14) 
or arsenite (Figure 16) stimulation experiments indicate that the ERK1/2 and the p38 pathways are 
involved in these phosphorylations. The functional signifi cance of these phosphorylation events is 
not clear yet. In the current model multiple signaling pathways converge on BRF1 and regulate its 
activity. 
However, we have to take in account, that BRF1 is only one player in the game. AREs can be bound 
by multiple AUBPs and the fate of the RNA depends on its affi nity to one specifi c set of AUBPs, 
their activation status and their local concentration. Despite the homology of the three destabilizing 
Tis11 family members BRF1, BRF2 and TTP, they seem to be differentially regulated. S203 is the 
only putative phosphorylation site present in all three proteins (Figure 19). Also, their expression 
is regulated differentially. Upon leukemia inhibitory factor (LIF) removal in embryonic stem (ES) 
cells, which triggers differentiation, TTP levels increase, whereas BRF1 and BRF2 levels decrease 
(Ines Raineri, unpublished data) or upon LPS stimulation in RAW macrophages TTP and BRF1 
expression is induced, whereas BRF2 is also expressed in unstimulated cells (Figure 17). Further, 
ARE-mRNA cannot only be stabilized by inactivation of decay promoting AUBPs, but also by 
activation of stabilizing components, such as HuR. In addition, regulation of yet unknown factors 
might modulate BRF1 activity. Increasing evidence indicates that mRNA turnover is tightly coupled 
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to translation and that cis-elements, such as the poly(A)-tail and the cap, play an important role in 
mRNA decay. To understand the complex interplay of all factors involved in the control of ARE-
mediated mRNA turnover, a lot more work needs to be invested.
.
Subcellular Localization of AUBPS
The two stabilizing AUBPs HuR and AUF1
p37
 are exported from the nucleus under conditions 
of ARE-mRNA stabilization. In accordance to previously published data, HuR and AUF1 were 
found to be shuttling proteins. Their predominant nuclear localization changes rapidly in response 
to different stimuli. These stimuli include activation of PI3-K, MEK6 but not PKB. Data by Ming et 
al. (Ming et al., 2001) showed that the p38 pathway, but not the PI3-K pathway, in combination with 
HuR overcome the strong destabilizing activity of TTP. These data suggest that HuR is regulated 
via the MEK6/p38 axis. The stabilizing activity of PI3-K, on the other hand, seems to be mediated 
mainly via PKB and inactivation of BRF1 (Schmidlin et al., 2004), which cannot antagonize another 
destabilizing activity by TTP, explaining the dominant effect of TTP over PI3-K. p38, on the other 
hand, seems to activate HuR activity, which can push the system in the direction of stabilization. 
However, the fact that PI3-K also affects HuR localization may be explained by another PI3-K 
downstream pathway different from PKB, e.g. the PKC pathway. TPA, a strong activator of 






















Figure 30: Model of BRF1 regulation. See text for details
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cytoplasm, strengthening the hypothesis that PKC is involved in shuttling of HuR and that PI3-K 
affects HuR localization rather via PKC than via PKB. 
Another signal affecting HuR localization has been reported by Wang et al. (Wang et al., 2002): 
AMP-activated kinase inhibits shuttling of HuR to the cytoplasm. In this study, the researchers 
further claim that the p38 and PI3-K pathways do not affect the subcellular distribution of HuR in 
RKO cells. These conclusions are based on experiments using inhibitors of p38 and PI3-K. As in 
NIH3T3 cells HuR predominantly localizes to the nucleus, a further decrease of cytoplasmic levels, 
which would be expected using the inhibitors, could not be measured. However, it may well be that 
not all kinases are of equal importance in different cell types. Another interesting observation is that 




 localization was affected by the same stimuli as HuR. MEK6, PI3-K, but not PKB did 
induce translocation of AUF1 to the cytoplasm. The role of AUF1 in mRNA turnover has not been 
clarifi ed yet. In NIH3T3 cells, transfection of the p37 isoform did result in stabilization of ARE-
mRNA (Ming, unpublished data). The co-regulation of AUF1 and HuR localization seems to assure 
effi cient stabilization of target mRNA. Recently, it has been shown that AUF1 and HuR target 
distinct but also common sites on the same mRNA (Lal et al., 2004). It is well possible that the two 
proteins cooperatively stabilize one particular set of mRNA. It would be interesting to investigate, 
whether AUF1 localization is regulated similarly in cells, where an mRNA destabilizing activity has 
been reported for this protein. In addition, the different isoforms seem to exert distinct effects on 
mRNA and nuclear export is facilitated by exon 7, which is only present in the two larger isoforms 
(Sarkar et al., 2003). In this thesis, only the localization of the p37 isoform was investigated. 
Therefore, it would also be interesting to compare the localization of the 4 isoforms in response to 
different stimuli. 
Treatment of cells with ActD did also lead to HuR and AUF1
p37
 export. The nuclear export of both 
proteins takes place in less than half an hour, observed in living cells. This is of particular interest, 
as mRNA turnover is routinely measured by inhibiting transcription with ActD. If localization of 
the AUBPs, indeed, affects the stability of mRNA, results from ActD chase studies have to be 
interpreted with great care. Reporter systems with inducible transcription have to be favored.
BRF1 and TTP are distributed all over the cell. Murata et al. showed nuclear and cytoplasmic 
localization of TTP in COS7 cells. Nuclear export was CRM1 dependent and a nuclear localization 
signal (NLS) could be mapped to the region between the two zinc fi ngers (Murata et al., 2002). Also 
for BRF1 and BRF2 CRM1 dependent shuttling was reported (Phillips et al., 2002). The authors of 
this publication confi rmed the presence of the NLS and in addition identifi ed a nuclear export signal 
(NES at the C-terminus of both BRF1 and TTP. The two reports differ in the point that in 293 cells 
TTP and BRF1 localized predominantly to the cytoplasm. Seemingly the localization is different 
in different cell types. In NIH3T3 cells the two proteins are distributed throughout the cell with 
some variations (Figure 25). The reason for these variations could not be fi gured out. The presence 




PI3-K stabilizes ARE-mRNA via inactivation of BRF1 and export of HuR. Interestingly, the two 
stabilizing proteins investigated here (HuR and AUF1
p37
) are stored in the nucleus under conditions 
of ARE-mRNA decay, whereas substantial levels of the two destabilizing proteins (BRF1 and TTP) 
are found in the cytoplasm. These fi ndings support the hypothesis that ARE-mRNA is targeted for 
rapid, exosomal turnover by BRF1 and/or TTP (Figure 31A). Upon stimulation, BRF1 and/or TTP 
are inactivated by phosphorylation, and/or HuR and AUF1 are exported into the cytoplasm, where 
they compete with the destabilizing factors for RNA binding and protect the RNA (Figure 31B). 
PI3-K seems to play an important role in the coordination of this process. As lined out in this thesis, 
activation of PI3-K, on one hand, promotes export of stabilizing HuR protein, probably via PKC, 
and on the other hand inactivates BRF1 by phosphorylating S92. Maybe, high concentrations of 
HuR are suffi cient to replace the inactivated BRF1 from the mRNA and protect it from degradation. 
Another possibility would be that inactive BRF1 and HuR bind together to one ARE, blocking the 
access of the exosome to the RNA. The fate of the ARE-mRNA is, therefore, determined by the 
activation status of the AUBPs as well as by the ratio of their local concentration.
Additional means of AUBP regulation. Two aspects of AUBP control have be investigated in this 
thesis: Localization and inactivation by binding of 14-3-3 in a phosphorylation dependent manner. 
In addition to that, also other ways of ARE-mRNA regulation have to be taken in account, including 
the turnover of AUBP mRNA and proteins. TTP was shown independently by two groups to interact 
with the 3’UTR of its own mRNA and promote degradation of its own message (Brooks et al., 





















Figure 31: The PI3-K signaling pathway controls ARE-mRNA stability via inactivation of destabilizing factors (BRF1) 
and activation of stabilizing factors (export of HuR)
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in our lab (Don Benjamin, unpublished data) indicate, that BRF1 protein stability is controlled by 
phosphorylation, displaying another way to regulate mRNA turnover.
Apart from the nucleo-cytoplasmic shuttling also other changes in AUBP localization may be of 
importance for their function. Upon oxidative stress several AUBPs, including HuR, TIA1, TIA-R, 
BRF1 and TTP, translocate into stress granules, where translationally silenced mRNA is stored 
(Kedersha et al., 1999; Kedersha et al., 2000; Stoecklin et al., 2004). Maybe, also other complexes 
exist, where AUBPs are stored in an inactive state, waiting for the appropriate stimuli.
Physiological Role of BRF1
BRF1 was initially cloned as an EGF-inducible and butyrate-repressible gene (Gomperts et al., 
1990). It was then found to bind and destabilize ARE-mRNA. However, it was not known, which 
ARE-mRNAs are targeted by BRF1 and what the physiological signifi cance of BRF1 is. 
Many cyclin and growth factor mRNAs contain AREs in their 3’UTR, and as HuR has been 
shown to control stability of cyclin mRNA in a cell cycle dependent manner (Wang et al., 2000), it 
seemed plausible, that the destabilizing BRF1 protein contributes to the rapid turnover of cell cycle 
regulating factors. Using a NIH3T3 cell line with doxycycline (dox)-repressible BRF1 expression, 
the role of BRF1 in cell cycle progression was investigated. Indeed, overexpression of BRF1 in 
these cells did accelerate the progression of serum starved, G0 arrested cells into S phase compared 
to cells with normal BRF1 levels. Downregulation of BRF1 by siRNA had the opposite effect. 
One way to explain this phenomena is that BRF1 destabilizes mRNA of cell cycle inhibitors (such 
as the cyclin-dependent kinase (CDK) inhibitors p15 (containing 3 AUUUA pentamers), p16 (2 
pentamers), p21 (2 pentamers) or p27 (7 pentamers); for review see (Sherr and Roberts, 1999)). Yet, 
the observed effect was reproducible but minimal and it seemed that BRF1 either does not directly 
regulate stability of one of the key players in cell cycle control or that BRF1 is only one component 
that acts in concert with other factors, such as TTP or HuR. In both cases, changing levels of BRF1 
would only have a marginal effect on the cycling behavior of the cells. 
Further insight into the physiological role of BRF1 was gained by work from Ines Raineri and 
coworkers (unpublished data) in our lab. Mouse embryonic stem cells (ES cells) can be cultured as 
pluripotent, self-renewing cells in the presence of Leukemia inhibitory factor (LIF). Upon removal 
of LIF, differentiation is induced. The cells, previously growing as compact colonies, start to 
spread out and differentiate into various cell types. Differentiation is accompanied by a prominent 
downregulation of BRF1 mRNA and protein. TTP mRNA levels, on the other hand, increase upon 
differentiation. Further, downregulation of endogenous BRF1 by siRNA induces a differentiation-
like phenotype of ES cells in the presence of LIF. Upon differentiation, cell cycle control of ES cells 
changes completely (Burdon et al., 2002). The fast cycling, self-renewing cells change to a slower 
cycle. This correlates with BRF1 downregulation in NIH3T3 cells, where cell cycle progression also 
seems to be slowed down. However, the data obtained from this set of experiments provide only 
a vague indication that BRF1 is a player in cell proliferation and no conclusion on any involved 




The work presented in this study provides insight into the mechanisms regulating ARE-mRNA 
turnover via AUBPs. Progress has been made in understanding the mode of action of BRF1, but 
still many questions remain unanswered and will be addressed in the future. The model presented in 
Figure 30 will have to be evaluated in respect to the nature of the different kinases, phosphorylating 
BRF1 and the functional signifi cance of these phosphorylation events. Is the affi nity of doubly 
(S92, S203) phosphorylated BRF1 to 14-3-3 higher? Does 14-3-3 binding inhibit exosomal 
targeting of ARE-mRNA by BRF1? Which kinase(s) do(es) phosphorylate S203. Are the other 
putative phosphorylation sites real? What is their functional signifi cance? By further characterizing 







M2135: 5’- ACA AGC TTC CAT GAC CGA G -3’ (pac:5’ (HindIII))
M2136: 5’- GGG CGG CCG CTC CTT TC -3’ (pac:3’ (NotI)
M2188: 5’- CCC TCG CCC TCG ATC TC -3’ (SPred reverse)
M2189: 5’- GGG CGG TAG GCG TGT ACG -3’ (SPCMV forward)
M2336: 5’- GGC GTG TAC GGT GGG AG -3’ (pminCMV forward)
M2337: 5’- GGA GAC AAT GGT TGT C –3’ (pTRE-myc poly(A) reverse)
TV334: 5’- GCG GTA GGC GTG TAC GGT GGG AGG –3’ (bsdhis-BRF1 forward)
TV335: 5’- CTG CCT GCT GGG GAG CCT GGG GAC –3’ (bsdhis-BRF1 reverse)
Primers for Northern Probes:
TV359: 5’- ACA GAT GTG ACA AGC CAA GG -3’ (ratVEGF)
TV360: 5’- GGT GTG TCT ATA GGA ATC C -3’ (ratVEGF)
M1170: 5’- ACT GTG TTG GCA TAG AGG TC -3’ (murine β-actin)
M1171: 5’- ACC TCA AAG AGA AGC TGT GC -3’ (murine β-actin)
M2352: 5’- TGA TGG TAC ATG CAA GGT GC -3’ (humanGAPDH)
M2353: 5’- ACA GTC CAT GCC ATC ACT GC -3’ (humanGAPDH)
Primers for Mutagenesis
TV277: 5’- GCC GAG TCC CCT CAC ATG TTT G -3’ (huBRF1 S283A forward)
TV278: 5’- CAT GGG CCG GAA GAG GAA GGT G -3’ (huBRF1 S283A reverse)
TV419: 5’- AGG AAT GCT GGA GGC GGG GAC GG -3’ (huBRF1 S203A reverse)
TV420: 5’- TTG CCT TTG CTG GGT TTC CCA GTG C -3’ (huBRF1 S203A forward)
Plasmids
bsd-HisBRF1wt has been described previously (Stoecklin et al., 2002). 
bsd-HisBRF1S90/92A (bsd-HisBRF1
AA
) is described in (Schmidlin et al., 2004).
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bsd-HisBRF1S203A was obtained by site directed mutagenesis of bsd-HisBRF1wt, using the 
primers TV419/420
bsd-HisBRF1S283A was obtained by site directed mutagenesis of bsd-HisBRF1wt, using the 
primers TV277/278.
pTet-Off, pTRE-myc were purchased from Clontech.
pTRE-myc-GFP was constructed by introducing the Afl II(blunt)-BfrI(blunt) fragment from MO-
GFP (containing GFP under the control of a Molony promoter and a SV40 poly(A) sequence) into 
the AatII(blunt) site of pTRE-myc.
pTRE-BRF1 contains a XbaI-KpnI(blunt) fragment from bsd-HisBRF1wt in the XbaI-SalI(blunt)site 
of pTRE-myc-GFP (Stoecklin et al., 2002). See Figure 32A.
pTRE-BRF1S90/92A contains a XbaI-KpnI(blunt) fragment from bsd-HisBRF1S90/92A in the 
XbaI-SalI(blunt)site of pTRE-myc-GFP (Stoecklin et al., 2002).
pTRE-TTP was constructed by introducing the XbaI(blunt)-HindIII(blunt) fragment of mTTP.tag 
(Stoecklin et al., 2000) into the HindIII(blunt) site of pTRE-myc-GFP. See Figure 32B.
pcDNA3.1-HuR-HIS/myc has been described in (Ming et al., 2001).
pHuR-green: The EcoRV/EcoRV fragment of pcDNA3.1-HuR-HIS/myc (Ming et al., 2001) was 
ligated into the EcoRV/SalI(blunt) cut pEGFP-N1 vector (Clontech). See Figure 33A.
pmAUF1-MycHis: was generated by introducing a HindII-EcoRV of mAUF1 into the respective 
site of pcDNA3.1/myc-HisB (Invitrogen).
pAUF1-green: The HindIII-EcoRV fragment from pmAUF1-mycHis (Ming) was ligated into the 
HindIII-SalI(blunt) cut pEGFP-N1 vector (Clontech). See Figure 33B.
pSRL was generated from pTet-BBB-AREGMCSF (Xu et al., 1998) by exchanging the blunted 
BamHI-BstXI fragment for the blunted BamHI-SphI fragment of pMXh-β-IL3(UTR)wt (Ming et 
al., 2001).
rasV12: pDCR-HA-rasV12 (Verheijen et al., 1999) was kindly provided by G. Radziwill and J.L. 
Bos.
RafCT: pcDNA3-Flag-rafCT (Heinrich et al. 2000) was kindly provided by K.Moelling. 
PI3-K: pEF-Bos-rCD2-p110 was generously provided by D. A. Cantrell (Reif et al., 1997; Reif et 
al., 1996).
m/pPKB: pECE.p-HA-PKBα (Andjelkovic et al., 1997) was kindly provided by B. A. Hemmings.
MEK6DD: SRα3-MEK6DD (Stein et al., 1996) was generously provided by M. Karin.
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p38-AGF: pCMV-p38-AGF (Raingeaud et al., 1995) was provided by R.J. Davis.
pMX-puro was constructed by inserting a HindIII/NotI PCR fragment (primers M2136/M2135) 
containing the puro sequence from pBABE-puro (Morgenstern and Land, 1990) into the respective 
sites from the pMX backbone kindly provided by T. Kitamura.
Transformation of E.coli (CaCl
2
-method)
DH5α E.coli cells were grown in 80ml LB medium to OD
600
 of 0.4-0.5. Cells were harvested by 
centrifugation at 2’500g and the pellet was resuspended in 50ml ice-cold 70mM CaCl
2
. Cells were 
incubated for 30min. Again cells were spinned down and resuspended in 2ml 70mM CaCl
2
 and 2ml 
50% glycerol. 100µl aliquots were stored at –70°C. For transformation the competent E.coli were 
thawed on ice. Then DNA (40-100ng) was added and put on ice for 25min. After 2min heat-shock 
at 42°C, the mixture was incubated for 1h in 1ml LB at 37°C. Then the cells were centrifuged, 
resuspended in 100µl LB and streaked on selective LB plates.
Isolation of Plasmid DNA
Plasmid DNA was purifi ed from DH5α E.coli strains using Plasmid Mini or Maxi kits® from 
QIAGEN according to the manufacturers protocol. DNA fragments from restriction digests or poly 
chain reactions (PCRs) were separated on agarose TAE-gel (Percentage dependent on the fragment 
size from 0.8 to 1.2%). The gel slices of interest were cut out and DNA was extracted using the 
MinElute Gel Extraction Kit® from QIAGEN. Alternatively DNA was purifi ed using the MinElute 
Reaction CleanUp Kit®.
DNA Cloning Techniques
Restriction enzyme digests and polymerase chain reactions were performed, using enzymes from 
Boehringer Mannheim, Roche or New England Biolabs (NEB). The protocols and buffers were 
adapted according to the conditions suggested by the suppliers.
Site Directed Mutagenesis
For site directed mutagenesis two back-to-back primers were designed containing the respective 
mutations. PCR was performed with TV277/TV278 (mutation of S283) or TV419/TV420 (mutation 
of S203) as primers using Platinum® Pfx DNA polymerase (Invitrogen). The reaction was digested 
with DpnI to specifi cally remove the methylated bacterial wild type template. The product was 
purifi ed over a TAE-agarose gel. The excised fragment was then purifi ed using the QIAquick Gel 
Extraction Kit® (QIAGEN) and ligated, before transformation into DH5α E.coli. The presence of 
the mutation was checked by sequencing and by restriction digest (for S283, where a BSMI was 
introduced by the PCR reaction).
Sequencing
Constructs were sequenced using the ABI Prism 310 Genetic Analyzer (Applied Biosystems) 
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or the CEQ 8000 (Beckman Coulter). The sequencing reaction was performed according to the 
manufacturers instructions.
Cell Culture and Transfection
Cell Lines
NIH3T3: Mouse fi broblast cells were grown in M2 medium (Iscove’s Modifi ed Dulbecco Medium 
(IMDM) supplemented with 10% fetal calf serum (FCS), 50µM 2-mercaptoethanol, 2mM glutamine, 
100U/ml penicillin and 100µg/ml streptomycin).
B2A2 cl23: NIH3T3 clone, expressing the tTA transactivator (Xu et al., 1998), was cultured as 
NIH3T3 cells.
BRF1off11 / BRF1off14: Two puromycin resistant B2A2 clones, stably expressing myc-BRF1 
under the control of a tetracycline repressible CMV promoter, were grown in M2 supplemented 
with 2µg/ml doxycycline.
HT1080: Human fi brosarcoma cells were grown in M2.
RAW 264.7: Mouse macrophages were also grown in M2 medium.
HIRc-B: Rat fi broblast cells, overexpressing the human insulin receptor (kindly provided by P. 
Blackshear (McClain et al., 1987)), were grown in Dulbecco’s Modifi ed Eagle’s Medium (DMEM) 
supplemented with FCS, 2-mercaptoethanol, glutamine, penicillin and streptomycin as in M2. 
MEF-PKBα-/- / MEF-PKBα+/+: PKB knockout mouse embryonic fi broblasts and the 
corresponding wt cells (kindly provided by B. Hemmings (Yang et al., 2003))were also grown in 
the same medium described for HIRc-B cells.
Transfection
Plasmids and siRNAs were transfected into cells using Lipofectamine 2000 reagent (Invitrogen) 
according to the manufacturers instructions.
Selection
For stable transfection of pTRE-BRF1wt into B2A2 cl23, pMX-puro was cotransfected and positive 
clones were selected by treating the cells with 2µg/ml puromycin. Clones, expressing the protein of 
interest were selected by Western blot.
RNAi
siRNA: 
BRF1 (mmBRF1): caa gau gcu caa cua cag c (nucleotides 130-148, NM_007564.1)




Cells were grown on cover slips (LabTek ChamberSlides, Nunc) pretreated with 0,1% gelatin. 
Then the cells were fi xed with 4% paraformaldehyde for 10 min. at RT before permeabilizing in 
Methanol or 0.1% Triton X100 for 2 min. Primary and secondary antibodies were added, diluted 
in 50µl M2 medium, serving as blocking reagent. Incubation with the antibodies lasted about 15 
minutes depending on the antibody. Between the different incubation steps the cells were washed 
intensively with PBS supplemented with Ca2+ and Mg2+. After the fi nal washing step the cells were 
mounted with Fluoromount-G® (Southern Biotechnology Associates, Inc.) and a coverslip. Cells 
were analyzed under the fl uorescence-microscope (Nikon) with the appropriate fi lters. Pictures were 
taken and prepared using the OpenLab software (Improvision)
Western Blot
Approximately 2.5x106 cells were grown to 80% confl uency. Medium was poured off and the cells 
were washed with PBS. At 4°C, 200µl M-PER® Mammalian Protein Extraction Reagent (Pierce) 
containing 1x Phosphatase inhibitor cocktails 1 and 2 (Sigma) was added to the plate for lysis. After 
5 minutes the cells were scraped off and transferred into Eppendorf tubes. The solution was vortexed 
and then centrifuged at 4°C. Supernatant was taken and protein concentration was measured using 
Bradford protein assay (BioRad). 30µg of total protein were denatured at 95°C for 2 minutes with 
sample loading buffer (Pierce) containing 1mM DTT before samples were loaded on 4-20% gradient 
SDS-polyacrylamide-gels (Anamed). Protein was blotted on Immobilon-P (Milipore) membrane 
and blocked for 1h in TBS containing 2% ECL Advance blocking reagent (Amersham) and 0.1% 
Tween-20 (TBS-T). The membrane was incubated over night at 4°C with the appropriate antibody 
diluted in TBS-T with blocking reagent. Before addition of the secondary antibody (pre-warmed to 
37°C) for 45 minutes, the membrane was washed in TBS-T. After fi nal washing, proteins of interest 
were visualized according to manufacturers protocol using CDP-star (Roche) or ECL advance 
(Amersham) depending on the secondary antibody and subsequent autoradiography.
Antibodies
Phospho-PKB (Ser473): mouse monoclonal IgG2b (clone 587F11), Cell Signaling Technology; 
PKB: rabbit polyclonal, Cell Signaling Technology (#9272); 
Phospho-p44/42 (Thr202/Tyr204) (Erk1/2): mouse monoclonal IgG1(clone E10), Cell Signaling 
Technology; 
p44/42 MAP Kinase: rabbit polyclonal, Cell Signaling Technology (#9102); 
Phospho-p38 MAPK: rabbit polyclonal (Thr180/Tyr182), Cell Signaling Technology (#9211); 
p38-MAPK: rabbit polyclonal, Cell Signaling Technology (#9212); 
HuR: mouse monoclonal (clone 3A2), Santa Cruz; 
Xpress: mouse monoclonal IgG1, Invitrogen;
α-tubulin: mouse monoclonal IgG1 (clone 236-10501), Molecular Probes; 
myc: monoclonal mouse (clone 9E10);
Secondary antibodies: Alexa-Fluor® 555 goat anti-mouse IgG(H+L); AP-coupled goat anti rabbit 









)-E-G-G-E-R-L (aa86 - aa98 of BRF1) and S-D-Q-E-
G-Y-L-S-S-S-S-S-S-H-S-G-S-D-S-P-T (amino acids 300-320) (Neosystem). The immune response 
of the animal was boosted twice in two-week intervals. One week after the second boost the rabbit 
was bled and the sera were tested for their ability to recognize recombinant (in vitro phosphorylated 
for the phospho-antibody) BRF1 on western blot. Positive sera were affi nity-purifi ed using the 
peptides mentioned above linked to activated CH Sepharose 4B (Pharmacia Biotech) according to 
the manufacturer’s protocol.
λ-Protein Phosphatase (λ-PPase)-Treatment
Cells were lysed as described before, without PPase inhibitors. The extract was supplemented with 
2mM MnCl. 10units of λ-PPase were added for indicated amounts of time at 30°C. The reaction was 
stopped by the addition of sample loading buffer and denaturation at 95°C.
In vitro Phosphorylation
The reaction was performed in 30mM Tris-HCl (pH 7.5), 5mM MgCl
2
, 1mM DTT, 0.2mM ATPγS 
(unlabelled or P32-labelled) with 4ng/µl rBRF1 and 10ng/µl activated PKB (kindly provided by B.A. 
Hemmings) for 30’ at 30°C (Yang et al., 2002).
Northern Blot Analysis
RNA Isolation
1-5x106 cells were grown to sub-confl uency in 10cm culture dishes. For ActinomycinD (ActD) 
chase experiments ActD was added at a concentration of 5µg/ml. After removal of the medium, 
cells were washed with PBS and subsequently RNA was extracted using the method described by 
N. Gough (Gough, 1988).
Electrophoreses and Blotting
20-50µg RNA were resolved on 1.1% agarose/formaldehyde gels in MOPS buffer (10mM MOPS 
(pH 7.0), 8mM Sodium acetate and 1mM EDTA (pH 8)) and blotted onto Highbond N+ membranes 
(Amersham) overnight with 20xSSC (1xSSC contains 150mM NaCl and 15mM Na-citrate (pH 7.0)). 
The membrane was prehybridized at 55°C (RNA probe) or 65°C (DNA probe) in corresponding 
hybridization buffer, before addition of the probe.
32P-Labelled RNA Probe
For SP6 in vitro transcription 1,5mM ATP, CTP, UTP, 1,25 µM GTP, 2,5mM DTT, 0,05mg/ml 
BSA (NEB), transcription buffer (Promega) linearized template DNA (amount dependent on the 
probe), 1U/µl SP6 polymerase (Promega) and 10µCi α32P-GTP were mixed and incubated at 37°C 
for 1hr. The probe was then phenol/chloroform extracted followed by ethanol precipitation. The 
probe was denatured at 95°C for 10min prior to addition to the blot. The blot was hybridized for 
16h in hybridization solution containing 50% (v/v) Formamide (Intergen Company). 5xSSC, 5x 
Denhardt’s solution (1% (w/v) Ficoll 400, 1% (w/v) polyvinylpyrrolidone, 1% (w/v) bovine serum 
albumin (Sigma, Fraction V)), 10ml PIPES (pH 6.4), 0.4mg/ml yeast RNA, 0.5% SDS and 5mM 
EDTA (pH 8.0). Then, it was washed with 2xSSC/0.2%SDS, followed by 0.2xSSC/0.2%SDS and 
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0.1xSSC/0.2%SDS for 30min each at 65°C. Then, the radioactive signal was visualized using a 
Phosphor-Imager (Molecular Dynamics) with the Quantity One software (BioRad).
For detection of IL3-3’UTR mRNA, an XbaI-EcoRI fragment of murine cDNA was used as a 
template for in vitro transcription. The template for the actin probe was a 260bp fragment of murine 
β-actin generated by RT-PCR using M1170 and M1171 as primers. 
32P-Labelled DNA Probe
For DNA probes, 25-50ng template, and 2pmol/µl primer in a total volume of 10µl were denatured 
at 95°C for 5min. Then 1x EcoPol reaction buffer (BioLabs), 0.5mM dNTPs (lacking dCTP), 
10µCi α32P-dCTP and 5U Klenov polymerase (exo- from BioLabs) were added and the mixture 
was incubated for 1h at 37°C. After purifi cation over the QIAquick purifi cation kit (QIAGEN) 
columns, the probe was denatured at 95°C for 5min and then added to the hybridization reaction. 
The hybridization solution for DNA probes contains: 6.8%SDS, 0.5M Na/PO
4
 (pH 7.2), 1% BSA 
(Sigma, Fraction V) and 2mM EDTA. The blot was hybridized overnight at 65°C and then, washed 
with 2xSSC/0.2%SDS and 0.2xSSC/0.2%SDS for 15 min each at 50°C. The radioactive signal 
was visualized using a Phosphor-Imager (Molecular Dynamics) with the Quantity One software 
(BioRad). For detection of ratVEGF mRNA, a 353nt long portion of the cDNA was amplifi ed by 
PCR with primers TV359 and TV360, and used as a template for a 32P-dCTP labelled, TV360-
primed DNA probe. For the GAPDH probe, a fragment of human GAPDH was amplifi ed by RT-
PCR using the M2352/M2353 primer pair was used as a template for the M2352 primed 32P-dCTP 
labelled DNA probe. 
Stripping
The blot was washed with boiling 0.5% SDS and prehybridized as described above, before addition 
of the new probe.
Propidium Iodide Staining
Cells were trypsinized and washed with PBS. After spinning them down, they were resuspended in 
PI-staining solution (50µg/ml propidium iodide, 0,1% tri-sodium citrate, 0,1% Triton X-100, 0,2mg/
ml RNase A) on ice. The samples were analyzed by fl ow cytometry using a red fi lter (580nm).
Methyl-3H-Thymidine Incorporation
Cells were grown in 96 well plates, serum-starved for 24h, then, FCS was added, 2h after addition 
of 0,5 µCi Methyl-3H-Thymidine/well. Cells were transferred to a fi lter paper and washed using the 
cell harvester from Inotech, then, incorporation of radioactivity was measured by a beta-counter 
(Packard).
Flow Cytometry






































































Figure 32: Map of pTRE-BRF1 and pTRE-TTP, allowing tetracycline controllable expressing of myc-tagged proteins. 
For selection, a GFP gene and an ampicillin resistance are located on the same plasmid. Restriction enzymes, cutting 




















































































Figure 33: Map of pHuR-green and pAUF1-green, expressing C-terminal GFP fusion proteins. In addition a kanamycin 
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